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Abstract
HIV-associated neurocognitive disorders (HAND) are a spectrum of HIV-related conditions affecting the
central nervous system that range from mild memory impairments to severe dementia. HAND results from
the release of inflammatory factors and excitotoxins by HIV-infected macrophages in the brain. These factors
alter the extracellular environment and provoke a neuronal response, ultimately causing dendritic damage,
synaptic loss, and neuronal death. Our previous data indicate that components of the cell cycle regulatory
machinery are elevated in neurons from post-mortem brain tissue of HAND patients. One of these
upregulated proteins, the transcription factor E2F1, is known to activate gene targets required for G1-to-S
phase progression as well as for apoptosis. Despite its increased neuronal expression, E2F1 target genes are
unchanged by HIV-induced neuronal damage in vitro. Furthermore, E2F1 displays a predominantly
cytoplasmic localization, a site inconsistent with its role as a transcription factor.
Utilizing an in vitro model of HIV-induced neurotoxicity, we assessed the role of E2F1 in HIV-mediated
neuronal damage. To begin, we evaluated the contributions of two death pathways - calpain-mediated and
caspase-mediated cell death - in cortical neurons treated with H2O2 and NMDA as they mature in culture.
Although both calpain-activated and caspase-activated death were detected in cortical neurons at 1 week of
age, only calpain-mediated neuronal death was observed at 3 weeks of age, suggesting that calpain is the
dominant death pathway. We then tested the effect of E2F1 gene disruption on HIV-induced neuronal loss.
Neuronal damage and death was significantly attenuated in neurons expressing mutant E2F1 protein
compared to wildtype cultures. Furthermore, we identified E2F1 as a novel calpain substrate and showed that
E2F1 cleavage by calpain produces an E2F1 fragment that stably accumulates in neurons during HIV-
mediated neuronal damage, suggesting a neurotoxic role for this E2F1 isoform. Finally, preliminary studies to
investigate a putative RNA-binding role for E2F1 in the neuronal cytosol are outlined. Together, these data
implicate E2F1 in a calpain-mediated pathway of HIV-induced neurotoxicity. Future work to understand the
role of E2F1 in neurons and the consequences of calpain cleavage of E2F1 could provide important insights
into disease progression and therapeutic strategies.
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ABSTRACT 
A ROLE FOR CELL CYCLE PROTEIN E2F1 IN HIV-INDUCED NEUROTOXICITY 
 
Jacob Zyskind 
 Kelly L. Jordan-Sciutto 
 
HIV-associated neurocognitive disorders (HAND) are a spectrum of HIV-related 
conditions affecting the central nervous system that range from mild memory 
impairments to severe dementia. HAND results from the release of inflammatory factors 
and excitotoxins by HIV-infected macrophages in the brain. These factors alter the 
extracellular environment and provoke a neuronal response, ultimately causing dendritic 
damage, synaptic loss, and neuronal death. Our previous data indicate that components of 
the cell cycle regulatory machinery are elevated in neurons from post-mortem brain tissue 
of HAND patients. One of these upregulated  proteins, the transcription factor E2F1, is 
known to activate gene targets required for G1-to-S phase progression as well as for 
apoptosis. Despite its increased neuronal expression, E2F1 target genes are unchanged by 
HIV-induced neuronal damage in vitro. Furthermore, E2F1 displays a predominantly 
cytoplasmic localization, a site inconsistent with its role as a transcription factor. 
  
  
v 
 
 Utilizing an in vitro model of HIV-induced neurotoxicity, we assessed the role of 
E2F1 in HIV-mediated neuronal damage. To begin, we evaluated the contributions of two 
death pathways – calpain-mediated and caspase-mediated cell death – in cortical neurons 
treated with H2O2 and NMDA as they mature in culture. Although both calpain-activated 
and caspase-activated death were detected in cortical neurons at 1 week of age, only 
calpain-mediated neuronal death was observed at 3 weeks of age, suggesting that calpain 
is the dominant death pathway. We then tested the effect of E2F1 gene disruption on 
HIV-induced neuronal loss. Neuronal damage and death was significantly attenuated in 
neurons expressing mutant E2F1 protein compared to wildtype cultures. Furthermore, we 
identified E2F1 as a novel calpain substrate and showed that E2F1 cleavage by calpain 
produces an E2F1 fragment that stably accumulates in neurons during HIV-mediated 
neuronal damage, suggesting a neurotoxic role for this E2F1 isoform. Finally, 
preliminary studies to investigate a putative RNA-binding role for E2F1 in the neuronal 
cytosol are outlined. Together, these data implicate E2F1 in a calpain-mediated pathway 
of HIV-induced neurotoxicity. Future work to understand the role of E2F1 in neurons and 
the consequences of calpain cleavage of E2F1 could provide important insights into 
disease progression and therapeutic strategies. 
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CHAPTER 1  -  INTRODUCTION 
 
1.1 HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS 
According to the most recent epidemiological data from the World Health Organization 
(WHO), over 35 million people are currently infected with the Human Immunodeficiency 
Virus (HIV). Although effective anti-viral therapy has been developed to slow disease 
progression, HIV remains a global health concern. In 2013 alone, WHO reported 2.1 
million people newly infected with HIV and 1.5 million HIV-related deaths. HIV is a 
retrovirus that can infect host cells expressing the surface glycoprotein CD4 and either 
the CCR5 or CXCR4 chemokine receptors. These proteins serve as surface receptors for 
the viral coat protein gp120 and mediate fusion of viral particles with the host cell 
membrane, allowing entry of the viral capsid and incorporation of the viral genome into 
the host cell DNA (Stevenson, 2003). After an initial latency period, viral replication 
increases and ultimately leads to host cell death and release of viral particles that spread 
the infection to remaining CD4-positive T-cells. The perpetuation of the infection 
ultimately depletes this population of T-cells, leaving the host susceptible to opportunistic 
infection (Stevenson, 2003).  This final stage of the infection is termed autoimmune 
deficiency syndrome (AIDS).  
In addition to the immunosuppressive effects for which it is best known, HIV also 
invades the central nervous system (CNS) and can cause neurological deficits 
characterized by motor, cognitive and behavioral abnormalities. These complications, 
collectively referred to as HIV-associated neurocognitive disorder (HAND), are 
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estimated to affect up to 30% of HIV-positive individuals (Sacktor et al., 2002, 
McArthur, 2004, Antinori et al., 2007). Symptoms range from mild impairments such as 
forgetfulness and agitation to a clinically demented state known as HIV-associated 
dementia (HAD) (Gonzalez-Scarano and Martin-Garcia, 2005). The neuropathological 
hallmarks underlying HAND consist of astrocytosis, syncytia formation, dendritic 
damage, synaptic loss and neuronal loss, which typically manifest in the cerebral cortex, 
hippocampus and basal ganglia (Gonzalez-Scarano and Martin-Garcia, 2005, Kaul et al., 
2005). While no genetic factors have been shown to increase the risk of HAND, 
susceptibility does correlate with high viral levels in the plasma (Childs et al., 1999). 
Following the widespread administration of anti-retroviral therapy (ART) and its 
effective suppression of viral replication, the incidence of HAND among HIV patients 
has decreased (Sacktor et al., 2002). However, the prevalence is increasing due to the 
longer life expectancy afforded by ART (Dore et al., 1999, McArthur, 2004, Gonzalez-
Scarano and Martin-Garcia, 2005).    
 HIV entry into the CNS occurs soon after systemic infection (Davis et al., 1992, 
An et al., 1999). Since the virus is unable to cross the blood brain barrier (BBB) itself, 
infiltration of the CNS occurs through a ‘Trojan Horse’ mechanism (Haase, 1986, 
Gonzalez-Scarano and Martin-Garcia, 2005). This process involves HIV-infected 
monocytes, some of which cross the BBB to replenish the population of resident 
macrophages and microglia that carry out immune surveillance in the brain (Gonzalez-
Scarano and Martin-Garcia, 2005, Kaul et al., 2005). Once inside the brain, these infected 
cells serve as viral reservoirs, releasing viral particles, viral proteins, and a host of soluble 
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factors such as chemokines, cytokines, trophic factors, reactive oxygen species, and 
excitotoxins into the extracellular milieu (Gonzalez-Scarano and Martin-Garcia, 2005, 
Kaul et al., 2005). These secreted factors activate and spread infection to nearby 
microglia and macrophages that in turn, release signaling molecules that further alter the 
extracellular environment (Gonzalez-Scarano and Martin-Garcia, 2005, Kaul et al., 
2005).  
Although neuronal loss is observed in HAND, HIV does not infect neurons due to 
their lack of CD4 receptor expression (Adle-Biassette et al., 1995, Petito and Roberts, 
1995). Neuronal death is instead mediated by HIV indirectly through the collection of 
factors released by the infected/activated macrophages and microglia in the brain 
(Gonzalez-Scarano and Martin-Garcia, 2005, Kaul et al., 2005).  Efforts to determine the 
neurotoxic contributions of individual factors have produced two potential models: the 
‘direct’ model which argues that secreted viral proteins are the major contributors to 
neurotoxicity (Hesselgesser et al., 1998, Kaul and Lipton, 1999, Ohagen et al., 1999), and 
the ‘indirect’ model which identifies the inflammatory factors released from activated 
macrophages and microglia as the key effectors of neuronal demise (Lipton et al., 1991, 
Achim et al., 1993, Bukrinsky et al., 1995). Although there is debate over the precise 
identity of the damaging factors, the altered extra-cellular environment triggers HIV-
mediated neuronal degeneration and death through neuronal pathways that respond to 
excitotoxicity and neuroinflammation (Kaul and Lipton, 2004). These pathways involve 
stimulation of glutamate receptors, protease activation, and upregulation of components 
of the cell cycle machinery (Jordan-Sciutto et al., 2002a, Jordan-Sciutto et al., 2002b, 
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Garden et al., 2004, Kaul and Lipton, 2006, O'Donnell et al., 2006, Akay et al., 2011). 
The subsequent sections will focus on some of these mechanisms as they relate to this 
body of work. 
  
1.2  CALPAIN STRUCTURE, REGULATION AND FUNCTION IN NEURONS 
 
Calpains are a family of cytoplasmic cysteine proteases that are activated by Ca
+2 
(Liu et 
al., 2008). They function as a major proteolytic system within the cell alongside the 
proteasome and autophagic lysosomal proteases. However, unlike these proteolytic 
systems, calpains do not degrade their substrates but instead proteolytically process them, 
leaving a truncated product that is either inactivated or functionally altered. There are 
currently 15 known Calpain isoforms in the human genome. These isoforms are broadly 
classified into two groups based on their domain structure: “classical” and “non-
classical” calpains. Classical calpains contain four domain regions, (1) an N-terminal 
anchor helix region, (2) a catalytic CysPc protease domain that consists of two protease 
core domains PC1 and PC2, (3) a C2 domain-like domain termed C2L that helps stabilize 
the protease core, and (4) a penta-EF-hand that binds Ca
2+
 at the C-terminus (Figure 1). 
Non-classical calpains lack the C2L domain and/or the penta-EF-hand domain.  
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Figure 1.1. Schematic of domain structure for calpain-1 and calpain-2.  The domain 
organization of the calpain-1 and calpain-2 heterodimers are laid out. The classical 
calpain domain structure is exemplified by the large catalytic subunit schematic. An N-
terminal helix segment, the protease core domain divided into subdomains PC1 and PC2; 
the C2-like domain C2L; and the penta-EF-hand domains of the large and small subunits 
PEF(L) and PEF(S) respectively. The small regulatory subunit also contains a glycine-
rich (GR) domain at its N-terminus. Domain boundaries are indicated by residue numbers 
flanking each domain. Adapted from Campbell and Davies, 2012.  
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The best characterized calpain isoforms are calpain-1 and calpain-2, two classical 
calpains that are ubiquitously expressed and heterodimerize with a small regulatory 
subunit encoded by CAPNS1/CAPN4 to form functional proteases. Both isoforms share 
the same domain architecture, contain ~60% sequence homology, and exhibit virtually 
identical substrate specificity in vitro. However, they display different in vitro 
requirements for Ca
2+
 in order to become activated. Half-maximal activity of calpain-1 
has been shown with in vitro Ca
2+
 concentrations of 3-50 uM, while calpain-2 achieves 
half-maximal activity
 
within a [Ca
2+
] range of 0.4-0.8 mM (Cong et al., 1989, Kapprell 
and Goll, 1989). Hence, calpain-1 and calpain-2 are often referred to as μ-calpain (for μM 
[Ca
2+
]) and m-calpain (for mM [Ca
2+
]), respectively.  Although the penta-EF hand 
domains of both calpain-1 and calpain-2 bind Ca
2+ 
ions, their primary function is to serve 
as the heterodimerization interface for the small regulatory subunit (Kretsinger, 1997, 
Maki et al., 2002).  In fact, the Ca
2+ 
binding of this domain does not trigger structural 
changes within the protease domain to turn the protease “on” or “off,” but rather provides 
structural support for the protease domain when it adopts an active conformation (Hanna 
et al., 2008, Moldoveanu et al., 2008). Instead, cooperative Ca
2+ 
binding at two sites 
within the catalytic CysPc protease domain – one site each in the PC1 and PC2 core 
domains – is responsible for protease activation (Dainese et al., 2002, Moldoveanu et al., 
2002, Moldoveanu et al., 2004). Ca
2+
 binding at these sites causes a conformational 
change within CysPc, bringing PC1 and PC2 closer together and positioning the catalytic 
cysteine, histidine and asparagine residues of the active site within the necessary 
proximity for proteolytic cleavage of the substrate protein (Moldoveanu et al., 2004).  
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The in vitro Ca
2+
 requirements for calpain-1 and especially calpain-2 activity are 
orders of magnitude higher than the nanomolar Ca
2+ 
concentration inside a resting cell. 
Given this barrier to activation, several mechanisms have been proposed to lower the 
[Ca
2+
] requirement and allow calpain activation in vivo. One mechanism that has been 
investigated is post-translational modification of calpain. Calpain-2 has been shown to be 
activated as a result of serine phosphorylation by ERK/MAPK. This activation was 
reported in cultured murine fibroblasts during epidermal growth factor (EGF)-induced 
cell motility and de-adhesion in the absence of intracellular Ca
2+ 
changes (Glading et al., 
2004).  Similarly, calpain-2 activation in neurons was also achieved by MAPK 
phosophorylation in response to both brain-derived neurotrophic factor (BDNF) and EGF 
signaling (Zadran et al., 2010). Another possible activation mechanism involves calpain 
binding to phospholipids along the plasma membrane. Several studies have highlighted 
the ability of calpain-1 and calpain-2 to bind polyphosphoinositides such as 
phosphoinositide biphosphate (PIP2) via their C2L domains (Saido et al., 1992, Tompa et 
al., 2001, Shao et al., 2006).  This interaction was shown to significantly lower the 
calcium requirement for protease activation (Saido et al., 1992).   This mechanism is 
particularly attractive given the convenient location of phospholipids to plasma 
membrane ionotropic receptors, and Ca
2+ 
channels on the ER and mitochondrial surface 
that facilitate rapid spikes of cytosolic [Ca
2+
]. By ensuring that calpain localizes near the 
center of these spikes, the cell can achieve rapid, brief periods of calpain activity in a 
spatially restricted fashion.  
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To date, the only endogenous specific inhibitor of calpains that has been 
identified is a protein called calpastatin. One calpastatin molecule contains four inhibitory 
units that can each bind and inhibit one calpain molecule (Emori et al., 1987, Maki et al., 
1987). Despite relatively poor calpastatin sequence conservation across species, the 
inhibitory effect on calpain is highly specific. Co-crystallization of calpastatin and 
calpain-2 has shown that calpastatin binds tightly to Ca
2+
-bound calpain while looping 
out several amino acids from the catalytic cleft, protecting itself from calpain cleavage 
(Moldoveanu et al., 2008).  Given that physiological activation of calpain is brief and that 
calpastatin knockout mice lack a phenotype under basal conditions, it seems likely that 
the inhibitory function of calpastatin is primarily involved during periods of stress to 
prevent prolonged over-activation of calpain (Takano et al., 2005). 
When transiently activated, calpains function in a diverse set of processes 
including cell adhesion and cell migration (Chan et al., Wiemer et al., Franco et al., 
2004), muscle contraction (Whidden et al., Verburg et al., 2009), and cytoskeletal 
dynamics (Franco et al., 2004, Wang et al., 2005). Calpain-1 and calpain-2 are 
ubiquitously expressed, and their deficiency through targeted deletion of the small 
regulatory subunit CAPN4/CAPNS1 causes embryonic lethality in mice (Arthur et al., 
2000, Zimmerman et al., 2000).  Both calpain isoforms are particularly abundant in the 
CNS and show expression in both neurons and glia (Goll et al., 2003).  Given the Ca
2+ 
influx in postsynaptic compartments mediated by NMDA receptors during synaptic 
transmission, a role for calpain in synaptic plasticity was hypothesized and has been 
studied for several decades. These studies have shown that induction of long-term 
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potentiation (LTP) by high frequency burst stimulation is blocked by application of 
calpain inhibitors such as leupeptin in both acute hippocampal slices and in vivo (Staubli 
et al., 1988, Oliver et al., 1989, Denny et al., 1990).  Furthermore, rats carrying a genetic 
deficiency in calpastatin show enhanced induction of hippocampal LTP following high 
frequency stimulation, suggesting that synaptic strength can be increased by promoting 
calpain activity (Muller et al., 1995).  
While the mechanism for this effect on synaptic potentiation is not fully 
elucidated, calpains have been shown to cleave numerous synaptic and cytoskeletal 
proteins that help establish LTP. Among them is the first identified calpain substrate αII-
spectrin, a neuronal cytoskeleton adaptor that is anchored to the plasma membrane and 
binds actin, calmodulin and microtubules (Siman et al., 1984). Cleavage of αII-spectrin 
has been shown to alter membrane domain organization and influence membrane 
trafficking events (Dosemeci and Reese, 1995). Calpains also proteolytically process 
membrane receptors responsible for synaptic transmission and plasticity such as AMPA 
receptors (AMPARs) and NMDA receptors (NMDARs) (Bi et al., 1997, Wu et al., 2005, 
Dong et al., 2006), synaptic scaffolding proteins PSD95 and SAP97 that are involved in 
trafficking and anchoring of AMPARs (Lu et al., 2000, Jourdi et al., 2005),  and 
postsynaptic kinases such as CamKII and Protein Kinase C that influence AMPAR and 
NMDAR conductance through receptor phosphorylation (Hrabetova and Sacktor, 1996, 
Hajimohammadreza et al., 1997). Finally, conditional disruption of calpain-1 and calpain-
2 in the mouse CNS via CAPNS1 deletion revealed reduced dendritic branching 
complexity, lower spine density and deficits in LTP and memory, providing further 
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evidence of calpain involvement in regulating neurotransmission and synaptic plasticy 
(Amini et al., 2013). 
 In addition to these physiological effects, calpains can have a detrimental impact 
on cell viability when over-activated. While physiological activation of calpain is brief, 
sustained dysregulation of calcium homeostasis during many neurodegenerative 
conditions  –  specifically those involving excitotoxicity  –  leads to prolonged calpain 
activation and cleavage of a wide range of substrates (Vosler et al., 2008). These cleaved 
substrates are either rendered inactive or display an altered function that contributes to 
disease pathogenesis. A well-studied example of these calpain-mediated functional 
alterations is the processing of neuronal kinase cyclin-dependent kinase 5 (CDK5), a 
protein involved in neuronal maturation and migration that is required for proper 
development of the mammalian cortex (Dhavan and Tsai, 2001, Tanaka et al., 2001). 
CDK5 activity is regulated through its interaction with p35, a small protein that serves as 
a regulatory subunit for the kinase (Tsai et al., 1994).  During pathological calpain 
activation, p35 is proteolytically cleaved to a smaller isoform p25, which aberrantly 
activates CDK5 and causes off-target phosphorylation of substrates such as NMDARs, 
the peroxidase Prx2, the cell cycle regulator Retinblastoma protein (Rb), and other 
disease-related proteins such as the ubiquitin ligase Parkin and the cytoskeletal protein 
Tau (Lopes and Agostinho, 2011).  
Sustained calpain activation has been reported in a number of chronic 
neurodegenerative states such as Alzheimer Disease (AD) (Saito et al., 1993, Kelly et al., 
2005), Parkinson’s Disease (PD)(Esteves et al., 2009), and Huntington’s Disease 
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(HD)(Gafni and Ellerby, 2002, Gafni et al., 2004) as well as acute conditions such as 
cerebral ischemia (Gascon et al., 2008). In AD, calpain activity has been a major focus of 
investigation. The protein Tau is best known for its involvement in AD neuropathology, 
producing intraneuronal aggregates termed ‘neurofibrillary tangles.’  Tau was first 
identified as a calpain substrate through cell-free studies, and later shown to be 
proteolytically processed by calpain-1 into a 17-kiloDalton fragment in cultured 
hippocampal neurons following treatment with Aβ oligomers (Yang and Ksiezak-Reding, 
1995, Park and Ferreira, 2005). Although initially identified as neurotoxic, a follow-up 
report suggests that the 17-kiloDalton fragment itself does not affect cell viability (Park 
and Ferreira, 2005, Garg et al., 2011).  Nonetheless, calpain appears to play a key role in 
disease progression. Immunohistochemical staining of AD post-mortem tissue revealed 
activated calpain-2 associated with neurofibrillary tangles and amyloid plaques, two of 
the major pathological features of the disease (Grynspan et al., 1997, Higuchi et al., 
2012).  Furthermore, manipulations of the calpain system both in cell culture and animal 
models of AD have been shown to alter disease pathology and neuronal impairments. For 
instance, mice lacking calpastatin show enhanced Aβ accumulation and Tau 
hyperphosphorylation (Higuchi et al., 2012). Pharmacological inhibition of calpains in a 
transgenic mouse model of AD attenuated synaptic dysfunction and cognitive impairment 
while reducing Aβ plaques and Tau hyperphosphorylation (Sinjoanu et al., 2008). These 
pathological alterations appeared to result in part from down-regulation of β-secretase 1 
leading to reduced production of Aβ40 and Aβ42 and from reduced activation of 
pathological Cdk5 activity, a kinase known to phosphorylate Tau (Sinjoanu et al., 2008). 
More recent studies have demonstrated that AD patients exhibit elevated calpain activity 
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in cerebrospinal fluid, suggesting that calpain activity may have diagnostic value in 
multi-variate analyses (Laske et al., 2014). 
Calpain activation has also been reported in PD, HD and HAND suggesting a 
widespread involvement in neurodegenerative conditions. The pathological protein 
aggregates called Lewy Bodies, which are a hallmark of PD, are primarily comprised of 
fibrillar α-synuclein protein (Jadhav et al., 2013). α-synuclein serves as a calpain 
substrate and has been shown to be cleaved by calpain both in its soluble form and as a 
fibrillized structure in vitro and that cleavage of fibrillized α-synuclein produces 
fragments that retain their fibril form and promote co-assembly of soluble α-synuclein 
(Mishizen-Eberz et al., 2003, Mishizen-Eberz et al., 2005).  Additionally, site-specific 
antibodies to calpain-cleaved α-synuclein fragments immunolabeled cortical tissue in 
aged PD transgenic mice and Lewy Bodies in the substantia nigra of PD patients post-
mortem (Dufty et al., 2007). Consistent with these findings, α-synuclein aggregation was 
reduced by calpastatin overexpression in α-syn transgenic mice, leading to reduced α-syn 
truncation and aggregation and improved maintenance of synaptic integrity (Diepenbroek 
et al., 2014).    
In the genetic neurodegenerative disease HD, a mutant form of huntingtin (mHtt) 
protein containing poly-glutamine (polyQ) repeat expansion shows a propensity to form 
intraneuronal inclusions in the striatum. These inclusions are comprised at least in part of 
N-terminal fragments of mHtt that have been proteolytically cleaved (Martindale et al., 
1998). Several reports have identified calpains as proteases responsible for this cleavage 
(Gafni and Ellerby, 2002, Gafni et al., 2004). Calpain-resistant forms of mHtt were 
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shown to attenuate toxicity produced by calpain activation in Htt-overexpressing cells 
(Gafni et al., 2004).  In addition, post-mortem tissue analysis of HD patients revealed 
elevated calpain activity in the caudate nucleus, pointing to a role for calpain in HD 
pathology (Gafni and Ellerby, 2002).   
Finally, a number of studies have implicated calpains in HAND. Using an in vitro 
model of HIV-induced neurotoxicity consisting of rat primary neuronal cultures treated 
with conditioned media from HIV-infected macrophages, we and others have shown that 
HIV-mediated neuronal damage is prevented by inhibiting NMDAR stimulation and 
calpain activation (O'Donnell et al., 2006, Wang et al., 2007, White et al., 2011). 
Investigation of the effect of HIV infection on CDK5 activation in cultured neurons 
revealed increased levels of the calpain-cleaved CDK5 activator p25 and higher CDK5 
activity following addition of HIV conditioned media (Wang et al., 2007). Similarly, 
examination of midfrontal cortex autopsy tissue from patients with HAND revealed 
elevated p25 levels, further suggesting that calpain activation in neurons is increased 
following HIV infection (Wang et al., 2007). In this same in vitro model, the pro-survival 
protein MDMx was shown to be degraded by calpain in neurons treated with HIV-
macrophage supernatants, causing neurotoxicity that was partially rescued by MDMx 
overexpression (Colacurcio et al., 2013). Finally, in a separate model of HIV-mediated 
neuronal damage, the HIV protein TAT was shown to activate calpain via ryanodine 
receptors, causing neuronal death that was attenuated using pharmacological inhibitors to 
ryanodine receptors and calpain (Perry et al., 2010). Together, these data provide a 
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compelling argument for the involvement of calpain activation in the neuronal damage of 
HAND.   
 Given this widespread involvement in neuronal damage, understanding the 
pathological activities of calpain and identifying its pathological substrates could provide 
insights into neuronal loss that are applicable to many diseases. Toward that end, several 
studies have attempted to uncover a preferred sequence for calpain cleavage (Tompa et 
al., 2004, Cuerrier et al., 2005). However, results have been inconclusive, and it now 
seems likely that calpain cleavage involves recognition of secondary or tertiary features, 
making substrate and cleavage site predictions more difficult. In spite of this challenge, 
understanding the various roles of calpain substrates and the functional implications of 
their proteolytic cleavage will provide critical insights into disease mechansims and 
potential therapeutic strategies. 
 
1.3  CASPASES: ROLES IN NEURONAL PHYSIOLOGY AND NEURONAL 
DEATH 
Caspases are a family of cysteine proteases best known for their role in mediating a type 
of programmed cell death called apoptosis that is characterized by DNA fragmentation 
and membrane blebbing. Caspases cleave their target substrates at tetrapeptide motifs 
where aspartic acid is in the P1 position. As with calpains, caspases are post-
translationally regulated to allow for their rapid activation. They are translated as inactive 
zymogens called procaspases and contain a large subunit, a small subunit, and an N-
terminal prodomain that must be proteolytically cleaved for enzyme activation. While 
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some caspases are primarily involved in immune regulation and cytokine processing, 
those that are implicated in apoptosis are typically classified into two groups – initiator 
caspases and executioner caspases. Initiator caspases (caspase-2, -8, -9, -10) are the first 
line of caspases to be activated following a death stimulus. They contain long N-terminal 
prodomains that facilitate interactions with specific adaptor proteins. These adaptors 
recruit and complex with the initiator caspases, allowing initiator caspase to aggregate 
and auto-activate through homodimerization and self- cleavage. Once activated, initiator 
caspases cleave and activate a second line of caspases termed executioner caspases 
(caspase-3, -6, -7).  These executioner caspases then go on to cleave a host of protein 
substrates that promote cell death.   
The above cascade can be triggered in response to a variety of pro-death stimuli, 
and the initial stimulus determines the identity of both the adaptor proteins and initiator 
caspases that participate. The influence of the initial stimulus can best be illustrated by 
comparing the two major apoptosis pathways that utilize the caspase cascade: the 
extrinsic pathway and intrinsic pathway (Figure 2). The extrinsic pathway is initiated by 
binding of ligands such as Fas ligand or tumor necrosis factor alpha (TNFα) to ‘death 
receptors’ on the cell surface (Lavrik et al., 2005). Death receptor binding  causes 
receptor clustering followed by recruitment of several adaptors such as Fas-associated 
protein with Death Domain (FADD), TNF receptor associated protein 2 (TRAF2), and 
cellular inhibitor of apoptosis proteins (cIAP1 and cIAP2) to form the death-inducing 
signaling complex (DISC). DISC formation, in turn, promotes binding and activation of 
initiator caspase-8 and caspase-10, leading to activation of the executioner caspases.  
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In the intrinsic (also called mitochondrial) pathway of apoptosis, cellular stresses 
such as growth factor deprivation, DNA damage, or developmental death signals cause 
mitochondrial membrane permeabilization and subsequent release of mitochondrial 
cytochrome c into the cytosol. This release promotes assembly of a protein complex 
called the ‘apoptosome, which consists of cytochrome c, apoptosis peptidase activating 
factor 1 (Apaf-1), and dATP. The apoptosome recruits and activates initiator caspase-9, 
leading to downstream activation of executioner caspases such as caspase-3 and 
ultimately cell death.  
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Figure 1.2. Schematic of Apoptotic Pathways. During intrinsic pathway activation, 
cellular stresses induce mitochondrial membrane permeabilization and cytochrome c 
release. Together with Apaf-1, cytochrome c forms the multimeric ‘apoptosome’ that 
recruits and activates caspase-7, which in turn activates executioner caspase-3 to carry 
out cell death.  In the extrinsic pathway, a death receptor ligand binds to the death 
receptor, triggers formation of a membrane-bound Death-Inducing Signaling Complex 
(DISC) involving the death receptor, adaptor proteins such as FADD, and recruitment of 
procasapase-8. Activation of caspase-8 leads to caspase-3 activation and apoptosis.  In 
some cell types, caspase-8 can also cleave pro-apoptotic protein Bid to tBid (dashed 
arrow), which interacts with Bax/Bak to trigger mitochondrial membrane 
permeabilization and induction of the intrinsic pathway.  
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Caspase-mediated cell death plays an important role in the developing nervous 
system.  Mice deficient in either caspase-3, caspase-9, or Apaf-1 display embryonic or 
perinatal lethality marked by exencephaly (Cecconi et al., 1998, Kuida et al., 1998, 
Pompeiano et al., 2000). This phenotype is due to reduced apoptosis in immature neurons 
and in neural progenitors, leading to their excessive amplification. Cell culture studies 
have also implicated caspase-dependent pathways in neuronal death following trophic 
factor deprivation. In cultured sympathetic neurons, nerve growth factor deprivation leads 
to apoptosis that can be blocked by caspase inhibitors (Deshmukh et al., 1996, McCarthy 
et al., 1997).  Programmed cell death has also been identified in regulating adult 
neurogenesis, the production of new postmitotic neurons in the adult brain. For instance, 
adult mice with genetic deficiency of BAX, a pro-apoptotic protein involved in 
mitochondrial release of cytochrome c, show an increased number of new neurons in the 
dentate gyrus and subcallosal zone, resulting from a reduced rate of programmed cell 
death among adult-generated neurons (Sun et al., 2004, Kim et al., 2011).    
Aside from their traditional roles in cell death, caspases have been implicated in a 
number of non-apoptotic cellular processes including cell differentiation, proliferation 
and inflammation (Yi et al., 2009). In the nervous system, it is now appreciated that 
caspases influence neuronal connectivity through several mechanisms including axon 
guidance, synaptic plasticity and dendritic pruning (Hyman and Yuan, 2012).  For 
instance, Casp9-/- mice exhibit aberrant olfactory sensory neuron projections to the 
olfactory bulb, possibly due to disruption of semaphorin 7A cleavage by caspase-9 at the 
axon surface (Ohsawa et al., 2009, Ohsawa et al., 2010). In hippocampal CA1 neurons 
from caspase-3 -/- mice,  experimentally induced NMDAR-dependent long-term 
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depression (LTD) is impaired, suggesting that caspase activation participates in synapse 
elimination and dendritic spine shrinkage (Li, Jia, Jo, 2010). Additionally, 
pharmacological inhibitors of caspases also block LTD and were shown to reduce AMPA 
receptor internalization, providing a potential mechanism for this caspase-mediated effect 
on synaptic transmission (Li et al., 2010).  Caspase activation has also been demonstrated 
to contribute to dendritic pruning. Through an elegant optogenetic approach that activates 
the intrinsic apoptotic pathway in dendrites, localized activation of caspase-9 and 
casepase-3 led to dendritic retraction and spine shrinkage while sparing the neurons from 
cell death (Erturk et al., 2014). These findings highlight the importance of caspases in 
neuronal physiological function and provide an attractive mechanism of localized caspase 
activation to carry out non-apoptotic functions in the CNS. 
Given the slow progression and chronic nature of most neurodegenerative 
conditions, it is thought to be unlikely that the typically rapid cell death brought on by 
classical apoptotic cascades could contribute to disease pathogenesis. However, evidence 
of caspase activation in a number of neurodegenerative disorders has been clearly 
documented.  Caspase activity has been shown both in tissue from Alzheimer Disease 
(AD) patients and in cell culture and animal models of the disease. For instance, caspase-
cleaved Tau fragments have been detected in neurofibrillary tangles and dystrophic 
neurites of hippocampal tissue from AD patients (Gamblin et al., 2003, Rissman et al., 
2004). Furthermore, cortical neuronal cultures treated with fibrillar Aβ42 display caspase 
activation and the same Tau fragments observed in vivo, and these caspase-cleaved Tau 
products accelerate Tau filament assembly in vitro (Gamblin et al., 2003).  In transgenic 
mice overexpressing Tau, caspase activation was shown to precede neurofibrillary tangle 
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formation, again suggesting that caspases play a role in catalyzing AD pathology (de 
Calignon et al., 2010).   
Reports of caspase involvement in neurodegeneration are not restricted to AD 
studies, but extend to other diseases as well. In Huntington ’s disease (HD), striatal 
neurodegeneration is accompanied by intraneuronal aggregation of toxic N-terminal 
fragments of mutant huntingtin (mHtt) protein.  Caspase-3 and Caspase-6 have both been 
shown to cleave mHtt and produce N-terminal fragments found in HD post-mortem brain 
tissue (Kim et al., 2001, Warby et al., 2008). Furthermore, caspase inhibition ameliorates 
mHtt toxicity in several cell models of mHtt toxicity (Wellington et al., 2000, Leyva et 
al., 2010).  Caspase processing is also thought to play a role in regulating the DNA- and 
RNA-binding protein TDP-43, a nuclear protein that redistributes to the neuronal cytosol 
and forms inclusions in a number of neurodegenerative diseases including ALS, 
Traumatic Brain Injury, and Frontotemporal dementia (Blennow et al., 2012, Baralle et 
al., 2013). Although a mechanism for TDP-43-mediated neurotoxicity is still not fully 
understood, several studies have identified caspase truncation of TDP-43 as enhancing 
aggregation and cellular toxicity, providing a possible link between TDP-43 pathology 
and neuronal damage in these diseases (Zhang et al., 2009, Yang et al., 2010, Yang et al., 
2014). Despite the growing number of studies implicating caspase activity in 
neurodegenerative states, further studies are warranted to determine whether caspases in 
mature neurons function within a classical apoptotic pathway or if local, transient 
activation of caspases are enacted for non-canonical processes. 
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1.4  E2F1:  STRUCTURE, REGULATION AND FUNCTION 
E2F1 is a member of the E2F family, a group of nine transcription factors best known for 
coordinating a transcription program that underlies cell cycle. The E2Fs are commonly 
divided into two subclasses based on their transcriptional regulatory properties: (1) 
“activator” E2Fs (E2F1-3a) which function as transcriptional activators and (2) 
“repressor” E2Fs (E2F3b-8) which repress transcription of target genes (DeGregori and 
Johnson, 2006). While all E2Fs share a highly homologous ‘winged helix’ DNA binding 
domain (Zheng et al., 1999), they display differences in their regulatory binding partners, 
functional capabilities and other structural features. 
  Human E2F1 protein is 437 amino acids in length. Located within the first 200 
amino acids is the ‘winged helix’ DNA binding domain (Zheng et al., 1999) (Figure 3). 
Next to the DNA binding domain is a dimerization domain, which allows E2F1 to 
heterodimerize with its DNA binding partner DP1. This interaction augments both DNA 
binding of E2F1 and transcriptional activation at target promoters (Helin et al., 1993, 
Bandara et al., 1994). At the C-terminus, E2F1 contains a transactivation domain, which 
promotes target gene transcription by recruiting the basal transcription subunit TFIID and 
several co-activators including acetylase p300/CBP to target promoters (Trouche et al., 
1996, Ross et al., 1999, Lang et al., 2001). p300/CBP boosts E2F1-mediated transcription 
both by increasing chromatin accessibility via histone acetylation and by acetylating 
E2F1 itself, leading to enhanced DNA binding and E2F1 stability (Martinez-Balbas et al., 
2000).  Embedded within the transactivation domain is the pRb binding motif. pRb 
binding to this motif during quiescence or early in the G1 phase masks the E2F1 
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transactivation domain, effectively repressing E2F1 activity (Helin et al., 1993). When 
pRb is phosphorylated by cyclin D:cdk4/6 just prior to S phase, pRb-E2F1 dissociates 
and E2F1 repression is relieved, allowing transcriptional upregulation of target genes. 
Finally, E2F1 also contains a cyclin A binding domain near its N-terminus (Xu et al., 
1994). Following S phase entry, this domain is bound by the cyclin A:cdk2 complex, 
inhibiting E2F1 binding to DNA (Krek et al., 1994, Krek et al., 1995). As the cell 
completes DNA replication, cyclin A:cdk2-bound E2F1 is ubiquitinated by the 
Skp1/Cul1/Skp2 ubiquitin ligase and subsequently degraded by the proteasome to allow 
entry to G2 (Marti et al., 1999). Finally, E2F1 contains nuclear localization signals at the 
N- and C-terminus that specify E2F1 nuclear targeting (Ivanova et al., 2007). 
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Figure 1.3. E2F1 domain organization. Pictured are the domains of E2F1. Cyclin A 
binding domain which facilitates cyclinA:cdk2 binding to E2F1, inhibiting E2F1 DNA 
binding and targeting E2F1 for proteasomal degradation, (aa 67-108), DNA binding (aa 
119-191) which contacts the nucleotides and the DNA backbone directly, 
Dimerization/Heptad Repeat (aa 201-243) which binds to the transcriptional co-factor 
DP1 to promote DNA binding, Marked Box (aa 245-317) domain which enhances E2F1-
DP1 dimerization, Nuclear localization signals (aa 85-91, 423-428) which retain E2F1 in 
the nucleus, Transactivation domain(aa 368-437) which facilitates interactions with basal 
transcription machinery or pRB binding through a pocket binding motif (aa 409-426).  
The blue horizontal bar maps the epitope that the KH95 E2F1 antibody detects (aa 342-
386). 
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The eukaryotic model of cell division involves the temporal regulation of a host 
of cell cycle proteins. For the cell cycle to proceed normally, cyclins and cyclin-
dependent kinases (CDKs) must coordinate their activity in a periodic and ordered 
fashion. The transcription factor E2F1 also takes part in this sequential regulation along 
with its repressor Retinoblastoma protein (pRb). In quiescence and in the early stages of 
the cell cycle, E2F1 is bound and repressed by pRb, preventing transactivation of target 
genes. During the G1 phase, pRb is phosphorylated by the cyclin D:cdk4/6 and cyclin 
E:cdk2 complexes, leading to dissociation of the repressive pRb-E2F1 complex (Giacinti 
and Giordano, 2006). E2F1 can then activate its targets, prompting S phase entry and 
DNA replication. 
  In mitotic cells, E2F1 expression is normally triggered by the presence of 
growth-promoting mitogens that stimulate cell cycle entry (DeGregori and Johnson, 
2006). However, maximal expression of E2F1 occurs late in G1 when E2F1 must 
transactivate target genes involved in DNA replication such as Pol-α, DHFR, and PCNA 
(DeGregori and Johnson, 2006). Because an E2F consensus site is located within its 
promoter, E2F1 is also able to upregulate its own mRNA levels, creating a positive 
feedback loop for its expression (Iaquinta and Lees, 2007). Translational control of E2F1 
occurs as well, most notably through miR 17-5p and 20a, which inhibit E2F1 protein 
synthesis during early G1 (Pickering et al., 2009).   
Aside from promoting cell proliferation, E2F1 functions as a potent and versatile 
inducer of apoptosis when DNA is irreparably damaged and in other contexts (DeGregori 
and Johnson, 2006). In such cases, E2F1 is stabilized by phosphorylation and protected 
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from degradation through an interaction with the phospho-serine binding protein 14-3-3τ 
(Wang et al., 2004, Iaquinta and Lees, 2007). As E2F1 accumulates, it can initiate 
apoptosis through direct transcriptional activation of apoptotic targets such as APAF-1, 
BAX, Puma, Bim, caspase 3, 7-9, and p14
ARF
. E2F1-mediated transcription can also 
trigger apoptosis through stabilization of the pro-apoptotic transcription factor p53 (Bates 
et al., 1998). p53 is typically maintained at low levels in the cell by the E3 ubiquitin 
ligase Mdm2, which shuttles p53 to the cytoplasm where it is degraded by the 
proteasome. Following E2F1 transactivation of p14
ARF
, p14
ARF
 sequesters Mdm2, 
causing p53 to accumulate and activate apoptotic targets (Bates et al., 1998, Putzer, 
2007). E2F1 can also promote cell death independently of p53 by transactivation of the 
p53 homolog, p73 (Irwin et al., 2000, Stiewe and Putzer, 2000). Alternatively, E2F1 can 
trigger cell death through several transcription-independent mechanisms: (1) directly 
binding p53 through the cyclin A binding domain (Hsieh et al., 2002) (2) reducing levels 
of an inhibitor of death receptor-mediated apoptosis TRAF2, possibly via reduction of the 
anti-apoptotic NF-κB (Phillips et al., 1999), and (3) activating the calcium-sensitive 
cysteine protease calpain, which leads to proteolytic degradation of the Mdm2 homolog 
and fellow p53 inhibitor, MDMx (Strachan et al., 2005) . 
1.5  E2F1 IN NEURONS 
E2F1 regulation and function as described in the previous section has been studied almost 
exclusively in cycling cells.  Neurons are considered to be permanently postmitotic. 
Given this designation, neuronal expression of cell cycle proteins might appear unlikely. 
However, E2F1 is indeed present in nervous tissue, beginning early in brain development 
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and increasing in expression through maturation (Kusek et al., 2001). This pattern of 
upregulation is reproduced in differentiated neural cell lines and primary neuronal 
cultures (Kusek et al., 2001). In stark contrast to the nuclear localization of E2F1 in 
proliferating cells, neuronal E2F1 is predominantly cytoplasmic (Wang et al., 2010). 
Furthermore, neuronal E2F1 exhibits active shuttling between the nucleus and cytosol in 
a Crm1a-dependent manner (unpublished). We have previously reported that 
immunostaining of E2F1 in cultured neurons reveals a punctate pattern and that 
biochemical fractionation of brain tissue reveals enrichment of E2F1 levels in synaptic 
fractions (Ting et al., 2014). These observations suggest E2F1 may have a novel function 
in postmitotic neurons. Interestingly, the ‘winged helix’ superfamily of DNA-binding 
proteins to which E2F1 belongs contains several members that physiologically bind RNA 
in the cytosol (Intine et al., 2003, Yoshizawa et al., 2005). Furthermore, several studies 
have demonstrated an ability of E2F1 to bind synthetic RNA species (Ishizaki et al., 
1996, Darbinian et al., 2006), suggesting a potential role for E2F1 as an RNA-binding 
protein in the neuronal cytosol. Despite this intriguing possibility, E2F1 in neurons does 
retain some of the properties it exhibits in undifferentiated cells. Chief among them is its 
transcriptional regulation of apoptosis. 
E2F1-dependent apoptosis has been studied extensively in neuronal culture 
preparations (Verdaguer et al., 2007). These studies have demonstrated that E2F1 
overexpression induces apoptosis in cultured cerebellar granule neurons, while E2F1 
deletion attenuates neuronal death caused by potassium deprivation, kainic acid 
treatment, and Aβ peptide application (Giovanni et al., 2000, O'Hare et al., 2000, Smith et 
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al., 2003). Furthermore, E2F1 induces neuronal apoptosis in a dopamine-evoked toxicity 
model through a transcription-independent reduction of TRAF2 (Hou et al., 2001).  
 
There are a number of in vivo examples demonstrating that neurons aberrantly 
upregulate E2F1 and other cell cycle proteins during  neurodegenerative disease (Herrup 
and Yang, 2007). Post-mortem analysis has revealed increased E2F1 expression in the 
substantia nigra of patients with PD, midfrontal cortex of AD patients, motor neurons of 
Amyotrophic Lateral Sclerosis patients, and brain tissue from Huntington’s Disease (HD) 
patients (Jordan-Sciutto et al., 2001, Ranganathan and Bowser, 2003, Hoglinger et al., 
2007, Pelegri et al., 2008). Upregulation of phosphorylated pRb has similarly been 
observed in some of these post-mortem samples (Jordan-Sciutto et al., 2001, 
Ranganathan and Bowser, 2003).  In human brain samples with HIV neuropathology and 
in simian models of HIV-related neurodegeneration, neuronal E2F1 levels are 
significantly increased in affected regions in comparison to those of infected patients 
lacking neuropathology (Jordan-Sciutto et al., 2000, Jordan-Sciutto et al., 2002b). 
Although neurons have never been observed to undergo complete cell divisions, neuronal 
DNA replication has been reported to coincide with upregulation of cell cycle proteins in 
AD and PD (Yang et al., 2001, Hoglinger et al., 2007). The above examples and other 
reports establish a clear link between the activation of cell cycle machinery and 
neurodegenerative states. Studying E2F1 and other cell cycle proteins in the context of 
neurodegeneration could advance our understanding of the neurotoxic mechanisms 
underlying these diseases. 
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1.6  RATIONALE AND OBJECTIVES 
As a result of its unique transcriptional regulation of the cell cycle and cell death, 
understanding E2F1-mediated transcriptional regulation has been a major point of 
emphasis. Initial studies of E2F1 in neuronal culture have focused on its ability to induce 
caspase-mediated neuronal apoptosis. Investigations into neurodegenerative mechanisms 
have revealed upregulation of E2F1 in CNS neurons of patients with a variety of 
neurodegenerative disorders. These observations have provided a theory whereby E2F1 
and other cell cycle regulators are aberrantly activated in neurons during 
neurodegenerative disease. This activation causes post-mitotic neurons to attempt to re-
enter the cell cycle and induces caspase-mediated neuronal death, both of which rely on 
E2F1 participation as a transcription factor. Interestingly, we have previously observed 
E2F1 neuronal expression to be predominantly cytoplasmic both in vitro and in vivo 
(Jordan-Sciutto et al., 2002b, Wang et al., 2010). Furthermore, we found that expression 
of canonical E2F target genes is unaffected in an in vitro model of HIV-induced 
neurotoxicity (Wang et al., 2010). Our past findings suggest that neuronal E2F1 may 
fulfill an alternate role to its traditional actions as a transcription factor.  
To explore this possibility, we first wanted to understand the availability of 
different death pathways to neurons as they mature (Chapter 2). We examined the relative 
contribution of two common death pathways: caspase-dependent apoptosis and calpain-
mediated cell death. We found that while both caspase- and calpain-mediated death 
pathways were activated in neurons at an early age in culture, only calpain-mediated 
death was observed as neuronal cultures matured. This developmental shift in death 
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pathway availability was associated with an upregulation of calpain-1 (μ-calpain) protein 
levels and a downregulation of executioner caspase-3 protein expression.  
Next, we sought to examine the role of E2F1 in the neuronal damage of HAND 
(Chapter 3). Utilizing an in vitro model of HIV-induced neurotoxicity, we assessed the 
effect of E2F1 gene disruption on HIV-induced neuronal loss. We found that neuronal 
damage and death was significantly attenuated in neurons expressing mutant E2F1 
protein compared to wildtype cultures. Furthermore, we identify E2F1 as a novel calpain 
substrate that is cleaved into a stable fragment in primary cortical cultures following 
treatment with HIV-macrophage conditioned media, suggesting that calpain-cleaved 
E2F1 may serve a neurotoxic role. Additionally, we demonstrate cell type-dependent 
processing of E2F1 by calpain, suggesting a novel mechanism of calpain regulation. 
In Chapter 4, we aimed to explore the possibility that E2F1 functions as an RNA-
binding protein in neurons. DNA binding domain To investigate putative RNA binding 
functions of E2F1 in the cytosol, we outline preliminary studies examining the RNA-
binding capability of E2F1 by attempting to define the key residues within the DNA 
binding domain that govern the E2F1-RNA interaction.  
Finally in Chapter 5, we provide a summary of our findings, an interpretation of 
their significance within the context of previous research, and their implications for 
future studies. We highlight potential areas for further examination, technical 
considerations for future experiments, and a discussion of clinical utility. 
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2.1  ABSTRACT 
Necrosis and apoptosis are well established as two primary cell death pathways. Mixed 
neuroglial cultures are commonly used to study cell death mechanisms in neural cells. 
However, the ages of these cultures vary across studies and little regard is given to how 
cell death processes may change as the cultures mature. To clarify whether neuroglial 
culture age affects cell death mechanisms, we treated 1-week-old and 3-week-old 
neuroglial cultures with either the excitotoxic stimulus, N-methyl-D-Aspartate (NMDA), 
or with the oxidative stressor, hydrogen peroxide (H2O2). While NMDA is known to be 
toxic only in cultures that are at least 2 weeks old, H2O2 is toxic in cultures of all ages. 
Here we confirm that, in 1-week-old neuroglial cultures, NMDA does not induce toxicity, 
while H2O2 induces both calpain-mediated and caspase-mediated neuronal death. In 3-
week-old cultures, NMDA and H2O2 both trigger calpain-mediated, but not caspase-
mediated, neuronal death. Further, we observed a decline in caspase-3 levels and an 
increase in calpain levels in untreated neuroglial cultures as they aged. Our findings 
presented here show that neuronal cell death mechanisms vary with culture age and 
highlight the necessity of considering culture age when interpreting neural cell culture 
data. 
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2.2  INTRODUCTION 
Neurons undergo cell death during both development and disease. Classically, cell death 
falls under two major categories. Apoptosis, considered a programmed cell death, is 
classified by specific cellular morphological changes such as membrane blebbing and 
nuclear fragmentation (Edinger and Thompson, 2004). The second major form of cell-
death is necrosis, classically defined as a passive and unregulated event (Edinger and 
Thompson, 2004). However, some reports have suggested that necrosis can also occur as 
part of a coordinated cell death program comparable to apoptosis and is not an 
uncontrolled event (Edinger and Thompson, 2004, Festjens et al., 2006). 
Caspases, a family of aspartate-specific cysteine proteases, are activated via 
proteolytic cleavage and are well-characterized for their role in apoptosis (Wyllie, 1997).  
Caspases fall into one of two groups: initiator caspases (8, 9, and 10) and their 
downstream targets, executioner caspases (3, 6, and 7). Activation of the initiator 
caspases serves to initiate apoptosis and can be triggered either extracellularly via 
stimulation of the Fas receptor and tumor necrosis factor receptor or intracellularly via 
the release of cytochrome c from mitochondria (Wyllie, 1997). The initiator caspases 
function to activate caspase-3 or another executioner caspase, which then executes 
apoptosis (Wyllie, 1997).  
Calpain is a ubiquitously expressed Ca
2+
-dependent neutral protease. While apoptosis 
is classically considered to be under the purview of the caspase family, calpain is now 
believed to play a role in apoptosis under certain conditions (O'Donovan et al., 2001). 
Calpain is also activated in neurological diseases in instances of both necrotic and 
apoptotic cell death (Heron et al., 1993, Bonfoco et al., 1995). Calpain is maintained as 
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an inactive proenzyme until a spike in cytosolic free Ca
2+ 
concentration triggers its 
activation. Cleavage targets of activated calpain comprise many enzymatic, signaling, 
and cytoskeletal proteins, including the neurofilament proteins, tau and tubulin (Ray and 
Banik, 2003). Importantly, calpain activity contributes to neuronal death in multiple 
neuropathlogical conditions, such as spinal cord injury (Ray and Banik, 2003), cerebral 
ischemia (Rami, 2003), and Alzheimer disease (Nixon et al., 1994). 
Attempts at uncovering the relative roles of caspases and calpains in neuronal death 
have been complicated by the post-mitotic nature of neurons. Unlike cycling cells, 
cultured neurons differentiate and mature as they age. Indeed, it is well-documented 
expression of certain proteins change as neuronal cultures age in vitro. For example, 
NMDA glutamate receptor expression is absent until approximately 14 days in vitro 
(DIV) and its subunit composition changes between 14 DIV and 21 DIV (O'Donnell et 
al., 2006). In previous studies of neuronal death, culture age has varied widely and the 
contributions of these age variations were not considered. Here, we examine the 
involvement of caspases and calpains in 1-week-old and 3-week-old neuroglial cultures 
responding to two different toxicities: NMDA, a toxicity known to depend on culture age, 
and hydrogen peroxide, which is toxic to neuronal cultures regardless of age (Nakamichi 
et al., 2005). 
2.3  MATERIALS AND METHODS 
Preparation of primary neuronal cultures. Primary rat neuroglial cortical cultures were 
prepared from embryonic day 17 Sprague–Dawley rat fetuses as described previously 
(Brewer, 1995). Cells were plated in dishes pre-coated with poly-L-lysine (Peptides 
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International, Louisville, KY, USA) at a density of 6 × 10
6
 cells per 100mm dish or 
4 × 10
4
 cells per well in 96-well plates and were maintained at 37°C, 5% CO2 in 
neurobasal media (Invitrogen) with B27 supplement (Invitrogen).  Neurons make up 90% 
of the total cells under these culture conditions [13].  
 
MAP2 cell-based ELISA assay.  Primary rat cortical neuroglial cultures were plated in 96-
well plates. Neuronal death and damage were assessed using a MAP2 cell-based ELISA 
assay, as described previously (White et al.). The reliability of the ELISA as an indicator 
of cell death was verified by traditional hand counting of MAP2-positive cells (White et 
al.).  
 
Western blotting of primary cell cultures. Whole cell extracts were prepared from 
primary rat cortical cultures and were subjected to Western blotting. Antibody dilutions 
are as follows: calpain-cleaved spectrin, 1:15,000 (gift from David Lynch, University of 
Pennsylvania);  u-calpain, 1:500 (#2556, Cell Signal, MA), caspase-3, 1:500 (#06735, 
Millipore, MA); caspase-9, 1:500 (#04443, Millipore, MA); caspase-8, 1:250 (AB1879, 
Millipore, MA); cleaved caspase-3, 1:250 (#9661, Cell Signal, MA). 
 
Statistical Analysis.   Differences between test groups were examined by one-way 
analysis of variance, with a threshold for significance of p<0.05.
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2.4  RESULTS 
Calpain, not caspase, mediates NMDA-induced neurotoxicity in 3-week-old cultures 
To elucidate age-related differences in neuronal death processes, we treated 1- and 3-
week-old mixed rat cortical cultures with varying doses of NMDA, the chemical agonist 
of the glutamate NMDA receptor. First, we examined cultures for neuronal damage and 
death using a cell-based (CB)-ELISA to detect the neuronal marker protein, microtubule-
associated protein 2 (MAP2). We found that, as expected, 1-week-old cultures showed no 
loss of MAP2 fluorescence when treated with NMDA, while 3-week-old cultures 
exhibited a significant decrease in MAP2 levels at all NMDA dosage levels (Figure 
2.1A). This decrease in MAP2 fluorescence was rescued by pretreatment with the calpain 
inhibitor MDL28170 (MDL), but not pan-caspase inhibitor qVD-OPH (OPH). As a 
positive control for protection, we also pretreated control cultures with the NMDA 
receptor antagonist, MK801, which completely blocks NMDA-induced toxicity. The 
result was confirmed by counting the number of MAP2-positive cells (Figure 2.1B). 
 To verify our pharmacological inhibitor data, we examined levels of calpain-
cleaved spectrin and executioner caspase-3 in our treated cultures to assess activation of 
each protease. As expected, we saw no increase in cleaved caspase-3 levels or in calpain-
cleaved spectrin levels in 1-week-old cultures following treatments with 3, 10, 30, or 
100M NMDA (Figure 2.1C). In 3-week-old cultures, NMDA treatment induced an 
increase in calpain-cleaved spectrin at all treatment doses. However, there was no 
increase in cleaved caspase-3 levels at any dose of NMDA treatment.  Taken together, 
these data suggest that calpain, rather than caspase-3, mediates NMDA-induced neuronal 
death in 3-week-old cultures. 
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Caspase and calpain activity both contribute to H2O2-induced toxicity in 1-week-old 
cultures, while toxicity in 3-week old cultures is mediated via calpain alone 
We next treated 1- and 3-week-old cultures with H2O2 to examine neuronal death 
processes following an insult known to induce toxicity in neuronal cultures regardless of 
age (Nakamichi et al., 2005). Specifically, we treated cortical neuroglial cultures with 30, 
100, or 300M H2O2 and examined neuronal death and damage using the MAP2 CB-
ELISA. In 1-week-old cultures, we observed significant MAP2 loss following treatment 
with either 100 or 300M H2O2; in 3-week-old cultures, all three doses of H2O2 induced 
significant reduction of MAP2 (Figure 2.2A). The decreased MAP2 fluorescence was 
rescued by pretreatment with MDL and OPH in 1-week cultures, but only by MDL in 3-
week cultures. The result is confirmed by counting the number of MAP2-positive cells 
(Figure 2.2B). 
When we immunoblotted lysates from H2O2-treated cultures for markers of 
protease activation, we found high levels of calpain-cleaved spectrin in both 1- and 3-
week-old cultures treated with 100 and 300M H2O2 and moderate levels of calpain-
cleaved spectrin in 3-week-old cultures treated with 30M H2O2 (Figure 2.2C). In 
support of our pharmacological inhibitor data, we observed increased levels of cleaved 
caspase-3 in 1-week-old cultures treated with 100M H2O2, but saw no increases in 
cleaved caspase-3 in 3-week-old cultures subjected to any doses of H2O2 (Figure 2.2C). 
Interestingly, we saw increased levels of cleaved caspase-3 in 1-week-old cultures treated 
with 30M H2O2, even though we had not observed MAP2-loss in these cultures. 
Further, we observed no increases in cleaved caspase-3 in 1-week-old cultures treated 
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with 300M H2O2, even though OPH protected against MAP2-loss induced at this dose. 
These findings suggest that in 1-week-old mixed cortical cultures, caspase-3 plays a role 
in H2O2-induced toxicity, particularly at lower doses, but does not contribute to H2O2-
mediated cell death in 3-week-old cultures. In contrast, calpain appears to mediate H2O2-
induced cell death in both 1-week-old and 3-week-old cultures. 
 
Calpain expression increases while caspase-3 expression decreases as neuroglial 
cultures age 
We next sought to determine whether 1- and 3-week-old cultures showed any difference 
in expression levels of calpains and caspases to determine whether our observed 
differences in protease responses to toxicities might occur solely at the 
cleavage/activation level, or whether differences in expression levels might also 
contribute. Thus, via immunoblot, we examined levels of -calpain, caspase-3, and of the 
initiator caspases, caspase-8 and -9 in 2-, 7-, 14-, and 21-day-old mixed cortical cultures. 
We found that levels of calpain increased with age and that full-length procaspase-3 
decreased (Figure 2.3). We saw no change in levels of full-length caspase-8 or -9. 
 
2.5  DISCUSSION 
In the present study, we highlight how the age of primary neuronal cultures influences the 
respective contributions of calpain and caspase to neuronal death. We investigated the 
role of calpain and caspase activation in two toxicity models, NMDA and H2O2, using rat 
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primary cortical neurons aged for 1 week and 3 weeks in culture. We found that 1-week-
old cultures treated with NMDA showed no significant calpain- or caspase-mediated 
toxicity, whereas NMDA treatment of 3-week-old neuronal cultures triggered calpain-
dependent neurotoxicity. H2O2 treatment of 1-week-old cultures produced both calpain 
and caspase-3 activation as well as calpain- and caspase-mediated neurotoxicity. In 
contrast, H2O2 treatment of neuronal cultures at 3 weeks of age primarily produced 
calpain-mediated toxicity. To investigate possible mechanisms for these age-dependent 
responses, we measured the expression of μ-calpain and caspase-3, -8 and -9 in primary 
neuronal cultures over time. We found that μ-calpain is expressed at higher levels as 
cultures age. In contrast, caspase-3 expression shows a decrease in protein levels as the 
cultures age. Together, our findings suggest that caspase-triggered death may play a 
major role in younger cultures, but that a calpain-mediated death pathway predominates 
as cultured neurons mature.  
Caspase activation has been reported to play an instrumental role in neurotoxicity 
caused by Aβ peptides, glutamate, and 6-hydroxydopamine, as well as that caused by 
serum withdrawal (Du et al., 1997, Marks et al., 1998, Giovanni et al., 2000, Hou et al., 
2001) . However, the primary neuronal cultures used in each of these studies have been 
aged for a week or less in vitro. The presence of caspase-dependent neuronal death in 1-
week-old cultures and its absence in 3-week-old cultures suggests that caspase 
involvement in neuronal death is greatest when the cells are immature and highlights the 
importance of culture age in studies examining death mechanisms in neurons, such as 
those mentioned above.  
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Further, although studies had previously suggested that excitotoxic challenge can 
trigger caspase-mediated apoptosis in cultured neurons (Bonfoco et al., 1995), a recent 
growing body of evidence has indicated that calpain pathways and not caspase pathways 
are predominantly responsible for excitotoxic death (Nimmrich et al., White et al., 
O'Donnell et al., 2006). Our observation that NMDA-mediated calpain activation and 
excitotoxic death only manifest in older neuronal cultures is similarly supported by 
several studies highlighting the developmental regulation of NMDA receptor expression 
in culture. These studies demonstrate (1) that NMDA-induced toxicity occurs selectively 
in mature neuronal cultures and that it can be blocked by application of the NMDA 
receptor antagonist MK-801, which blocks open channels on the cell surface, and (2) that 
excitotoxicity-sensitive NR2A and NR2B subunits are highly expressed between 14 DIV 
and 21 DIV, but are nearly undetectable at 7 DIV (Eugenin et al., O'Donnell et al., 2006). 
Consequently, the presence of NR2-containing NMDA receptor subtypes leads to an 
increased excitotoxic death in older cultures. 
The increase in μ-calpain protein expression along with the decrease in caspase-3 
expression as our cultures age may partially explain the absence of caspase-dependent 
neurotoxicity following toxic treatments of our 3-week-old primary neuronal cultures. 
Interestingly, these converse patterns of calpain and caspase-3 protein expression were 
previously reported by others using primary rat cortical cultures aged between 5 days and 
20 days in vitro (Kim et al., 2007). A number of in vivo studies have also examined 
temporal expression of these proteases during rat brain development. They similarly 
found that procaspase-3 protein and mRNA levels fall off dramatically in the cortex and 
in brain homogenates during central nervous system maturation (Hu et al., 2000, 
 50 
 
Yakovlev et al., 2001, Li et al., 2009). These reports are accompanied by functional 
studies demonstrating a progressively reduced ability to activate caspases in neurons as 
they mature in culture and in vivo (Hu et al., 2000, Yakovlev et al., 2001). In contrast, 
upregulation of calpain mRNA and protein levels has been repeatedly observed as brains 
age and undergo neurodegeneration, with abnormally high levels observed in the 
neocortex of Alzheimer’s Disease patients and substantia nigra and locus coeruleus of 
Parkinson’s Disease patients (Nixon et al., 1994, Mouatt-Prigent et al., 1996, Li et al., 
2009).  
While 1-week-old cultures treated with H2O2 showed an accumulation of cleaved 
caspase-3, 3-week-old cultures treated with either NMDA or H2O2 showed no caspase-3 
activation. Procaspase-3 levels were nonetheless detectable in our 3-week cultures and 
were noticeably reduced by higher concentrations of NMDA and H2O2. Interestingly, 
this reduction was typically accompanied by calpain activation observed by increased 
calpain-cleaved spectrin, suggesting that 3-week-old neuronal cultures may utilize 
calpain-mediated proteolysis or degradation of caspase-3 as a mechanism to silence 
caspase signaling. Indeed, crosstalk between the calpain and caspase pathways has been 
reported in several instances, with calpain typically acting upstream of caspases, cleaving 
caspase-3 as well as caspase-7, -8, and -9 at non-canonical sites rendering them inactive 
(Chua et al., 2000).  
Our results strongly suggest that the caspase-dependent death pathway is active in 
developing neuronal cultures but is replaced by calpain as the predominant death pathway 
when cultured neurons mature. We suggest two potential mechanisms that underlie this 
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change: (1) calpain-mediated inactivation of caspases (Fig. 1 & 2) and (2) 
downregulation of procaspase expression as neurons age (Fig. 3). Both mechanisms may 
be at play as neurons age. Given our findings, in vitro studies of caspase involvement in 
neuronal death should be interpreted with careful consideration given to the age of 
culture. 
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Figure 2.1 Calpain mediates NMDA-induced neurotoxicity in 3-week-old cultures. A, 
MAP2-cell based ELISA was performed in one or three-week old rat cortical cultures in 
response to 3, 10, and 30M NMDA.  NMDA has no effect on the MAP2 fluorescence 
signal strength in 1-week old rat cortical cultures. In 3-week old rat cortical cultures 
NMDA induced a dose-dependent decrease of the fluorescence signal strength in MAP2-
cell based ELISA, and the decrease is blocked by the calpain inhibitor MDL28170, and 
by the NMDA receptor antagonist, MK801, but is not affected by the caspase inhibitor, 
OPH (*** p<0.001, compared with veh; ###p<0.001, compared with cells treated with 
30M NMDA). B, Neuronal survival as determined by counts of MAP2-positive cells in 
one or three-week old rat cortical cultures in response to 3, 10, and 30M NMDA.   Data 
represents the average ±SD counts of multiple wells (n=6; *** p<0.001, compared with 
veh; ###p<0.001, compared with cells treated with 30M NMDA). C,  One and three-
week old rat cortical cultures were treated with 3, 10, 30, or 100M NMDA, and the 
expression levels of calpain-cleaved spectrin, caspase-3, and cleaved caspase-3 were 
detected (n=3) by western blot. The fold change in protein expression compared to that of 
the control (1.0) is specified beneath the respective bands in each blot. Each sample was 
subjected to SDS-PAGE and stained with Coomassie blue to demonstrate equal loading 
of samples. 
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Figure 2.2 Caspase and calpain activity both contribute to H2O2-induced toxicity in 
1-week-old cultures, while toxicity in 3-week old cultures is mediated via calpain. A, 
MAP2-cell based ELISA was performed in one or three-week old rat cortical cultures in 
response to hydrogen peroxide. In 1-week-old rat cortical cultures, hydrogen peroxide 
induced a dose-dependent decrease of the fluorescence signal strength in MAP2-cell 
based ELISA, and the decrease is blocked by calpain inhibitor, MDL28170, and caspase 
inhibitor, OPH. In 3-week-old rat cortical cultures hydrogen peroxide induced a dose-
dependent decrease of the fluorescence signal strength in MAP2-cell based ELISA, and 
the decrease is blocked by MDL28170, but not by OPH. B, Neuronal survival as 
determined by counts of MAP2-positive cells in one or three-week old rat cortical 
cultures in response to hydrogen peroxide. Data represents the average ±SD counts of 
multiple wells (n=6; *** p<0.001, compared with veh; #p<0.05, ### p<0.001, compared 
with cells treated with 300M hydrogen peroxide). C, One or 3-week-old rat cortical 
cultures were treated with different concentrations of hydrogen peroxide and expression 
levels of calpain-cleaved spectrin, caspase-3, and cleaved caspase-3 were detected (n=3). 
The numerical values specified beneath the respective bands of western blots represent 
the fold change in protein expression as compared with that of the control (1.0). Each 
sample was subjected to SDS-PAGE and stained with Coomassie blue to demonstrate 
equal loading of samples. 
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Figure 2.3 Representative blot showing age-dependent expressions of calpain and of 
full-length caspases: 3, 8, and 9. Expression levels of calpain, caspase-3, casapse-8, 
caspase-9 were detected in d2, d7, d14, and d21 rat cortical cultures (n=3). The numerical 
values specified beneath the respective bands of western blots represent the fold change 
in protein expression as compared with that of the control (1.0). Each sample was 
subjected to SDS-PAGE and stained with Coomassie blue to demonstrate equal loading 
of samples. 
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3.1  ABSTRACT 
The transcription factor E2F1 activates gene targets required for G1-S phase progression 
and for apoptosis, and exhibits increased expression levels in neurons in several CNS 
diseases including HIV encephalitis, Alzheimer disease, and Parkinson Disease. While 
E2F1 is known to regulate cell viability through activation of caspases, here we present 
evidence supporting the involvement of E2F1 in NMDA receptor-dependent, HIV-
induced neuronal death mediated by calpains. Using an in vitro model of HIV-induced 
neurotoxicity that is dependent on NMDA receptor and calpain activation, we have 
shown that cortical neurons lacking functional E2F1 are less susceptible to neuronal 
death.  Additionally, we report that neuronal E2F1 is cleaved by calpain to a stable 55-
kiloDalton fragment following NR2B-dependent NMDA receptor stimulation.  This 
cleavage of E2F1 is protein conformation-dependent and involves at least two cleavage 
events, one at each terminus of the protein. Intriguingly, the stabilized E2F1 cleavage 
product is produced in postmitotic neurons of all ages, but fails to be stabilized in cycling 
cells. Finally, we show that a matching E2F1 cleavage product is produced in human fetal 
neurons, suggesting that calpain cleavage of E2F1 may be produced in human cortical 
tissue. These results suggest neuronal E2F1 is processed in a novel manner in response to 
NMDA receptor-mediated toxicity, a mechanism implicated in HAND pathogenesis as 
well as several other diseases of the CNS. 
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3.2  INTRODUCTION 
E2F1 is a highly conserved member of the E2F family, a group of nine transcription 
factors that coordinate a transcription program underlying cell cycle progression. E2F1-
directed transcription is mediated by coordinated activity of the ‘winged helix’ DNA 
binding domain and C-terminal transactivation domain, which recruit basal transcription 
machinery to target gene promoters(Trouche et al., 1996, Ross et al., 1999, Lang et al., 
2001). Embedded within the transactivation domain is the pocket binding motif for tumor 
suppressor Retinoblastoma protein (pRb), which binds E2F1 during quiescence and G1 to 
repress E2F1 activity (Helin et al., 1993, Lees et al., 1993). Hyperphosphorylation of pRb 
prior to S phase leads to dissociation of the pRb-E2F1 repressive complex allowing E2F1 
to transactivate target genes involved in DNA replication such as DNA polymerase-α, 
dihydrofloate reductase, and proliferating cell nuclear antigen (DeGregori and Johnson, 
2006).  
Aside from promoting cell proliferation, E2F1 functions as a potent inducer of 
apoptosis both in response to cytotoxic events such as irreparable DNA damage and 
during normal physiologic processes like T-cell maturation (DeGregori and Johnson, 
2006). In these cases, E2F1 is stabilized by phosphorylation and protected from 
degradation through an interaction with the protein 14-3-3τ (Wang et al., 2004, Iaquinta 
and Lees, 2007). As E2F1 accumulates, it can initiate apoptosis through transactivation of 
apoptotic targets such as Bax, caspase 3, 7-9, and p14
ARF
. Alternatively, E2F1 can trigger 
cell death through multiple transcription-independent mechanisms, by inhibiting 
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activation of anti-apoptotic signals such as NFkappa-B, reducing levels of TRAF2, and 
inducing activation of calcium-sensitive cysteine protease calpain, which leads to 
proteolytic degradation of the Mdm2 homolog and p53 inhibitor, MDMx (Phillips et al., 
1999, Hou et al., 2001, Strachan et al., 2005). 
E2F1 regulation and function has been studied primarily in cycling cells. Little is 
known about the role of E2F1 in post-mitotic neurons. E2F1 is present in neurons during 
brain development and increases in expression through neuronal maturation (Kusek et al., 
2001). This upregulation is also observed in differentiation of neural cell lines and 
cultured primary neurons (Kusek et al., 2001, Ting et al., 2014). In contrast to the nuclear 
localization of E2F1 in proliferating cells, neuronal E2F1 is predominantly cytoplasmic 
(Wang et al., 2010). Although neuronal E2F1 does retain some properties observed in 
mitotic cells, including its ability to induce apoptosis, these observations suggest E2F1 
may have a novel function in neurons. 
E2F1 deletion in vitro attenuates neuronal death in a number of toxicity models 
including potassium deprivation and Aβ peptide toxicity, while upregulation of E2F1 has 
been observed in post-mortem brain tissue of patients with Alzheimer Disease (AD), 
Parkinson Disease (PD) and Amyotrophic Lateral Sclerosis (ALS), supporting a link 
between E2F1, neuronal viability and neurodegeneration (Giovanni et al., 2000, O'Hare 
et al., 2000, Jordan-Sciutto et al., 2001, Ranganathan and Bowser, 2003, Hoglinger et al., 
2007). HIV-associated neurocognitive disorder (HAND) is a neurologic syndrome 
consisting of a spectrum of cognitive, motor and behavioral deficits. Although neurons 
themselves are not directly infected by HIV, neuropathological hallmarks of the disease 
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include dendritic damage, synaptic loss and neuronal loss (Masliah et al., 1992, Masliah 
et al., 1997). Infiltration of HIV-infected macrophages into the central nervous system 
precedes neuronal damage. Such macrophages and subsequently activated resident 
microglia secrete inflammatory factors that alter the extracellular environment (Giulian et 
al., 1996, Gonzalez-Scarano and Martin-Garcia, 2005). The neuronal response to the 
altered environment involves aberrant activation of the cell cycle regulatory machinery, 
including upregulation of E2F1 (Wang et al., 2007, Akay et al., 2011). Post-mortem 
tissue from patients with HIV encephalitis (HIVE), the pathological correlate of advanced 
disease, shows elevated levels of E2F1 in neurons from basal ganglia, hippocampus and 
prefrontal cortex, the brain regions most affected in HAND (Jordan-Sciutto et al., 2002), 
although prototypical E2F1 target genes remain unchanged (Wang et al., 2010). 
Interestingly, the E2F1 observed in tissue from patients with HIVE is also primarily 
cytoplasmic.  Similar results were observed in cortical samples from SIV-infected 
encephalitic macaques (Jordan-Sciutto et al., 2000). These findings suggest that E2F1 
correlates with HAND but likely fulfills a different function from its classical role as a 
nuclear transcription factor, 
Our lab has previously shown that E2F1 is processed by calpain in dividing cells  and 
overexpression of a cytoplasmic and transcriptionally-inactive E2F1 protein in dividing 
cells leads to calpain activation and calpain-dependent toxicity (Strachan et al., 2005).  
Although calpain is ubiquitously expressed, it is particularly abundant in the CNS. 
Calpain has also been implicated in synaptic potentiation (Khoutorsky and Spira, 2009, 
Zadran et al., 2009) transcriptional regulation (Abe and Takeichi, 2007, Lynch and 
Gleichman, 2007, Khoutorsky and Spira, 2009, Zadran et al., 2009) and in both acute and 
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chronic neurodegeneration (Saito et al., 1993, Gafni and Ellerby, 2002, Gafni et al., 2004, 
Kelly et al., 2005, Gascon et al., 2008, Esteves et al., 2009). Calpain has two prototypical 
isoforms, μ-calpain and m-calpain, that differ in their in vitro requirements for Ca+2 (μM 
for μ-calpain, mM for m-calpain). Although they display nearly identical substrate 
specificity, μ-calpain activation is associated with neuroprotective processes and m-
calpain activation may contribute to pathologic states (Wang et al., 2013). Sustained 
dysregulation of calcium homeostasis during many neurodegenerative conditions, 
specifically those involving excitotoxicity, leads to calpain cleavage of a wide range of 
substrates (Vosler et al., 2008). These cleaved substrates are either rendered inactive or 
display an altered function that may contribute to disease pathogenesis. Given these 
findings, we assessed the interplay of E2F1 and calpain in a calpain-dependent model of 
neurotoxicity utilizing an in vitro model of HIV-mediated neuronal damage. 
 
3.3  MATERIALS AND METHODS 
Animals: E2F1
tm1
 transgenic mutant and wild-type mice are C57BL6/SV129 hybrids 
obtained from Jackson Labs (Bar Harbor, ME). Mice were housed under a 12-hr 
light/dark cycle and were allowed access to food and water ad libitum. Experiments were 
approved by the Institutional Animal Use and Care Committee and in accordance with 
the ARRIVE guidelines. 
 
Chemicals and reagents: Antibodies used include: Actin (A2066), MAT (M6693) 
[Sigma], Akt1 (#2938), phospho-Akt1 (#4060), Erk1/2 (#4695), phospho-Erk1/2 
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(#9101), FLAG (#2368), Lamin A/C (#2032) [Cell Signaling], E2F1 (KH95), GAPDH 
(6C5) [Santa Cruz], MAP2 (SMI52) [Covance]. Calpain-cleaved aII-spectrin (A38) 
described previously (Roberts-Lewis et al., 1994) was a generous gift from Dr. Robert 
Siman (University of Pennsylvania). Other chemicals include N-methyl-d-Aspartate 
(NMDA), NMDA inhibitor MK801 (Tocris), calpain inhibitor MDL28170 (Tocris), 
recombinant calpain-1 (208712, Calbiochem), Nicotinamide (Sigma), Trichostatin A 
(Sigma), Lambda protein phosphatase (New England Biolabs), Conantokin G (Bachem), 
and Ifenprodil (Tocris), Goat anti-mouse-beta-lactamase TEM-1-conjugated secondary 
antibody and Fluorocillin
TM
 Green reagent were from Invitrogen. 
 
Preparation of primary neuronal cultures: Primary cortical cultures were prepared 
from E18 Sprague Dawley rat embryos or E16 murine embryos as described previously 
(Wang et al., 2007). Cells were plated on poly-L-lysine pre-coated 60mm dishes at a 
density of 2 x 10
6
 cells per dish and maintained in neurobasal media with B27 
supplement (Invitrogen) at 37°C, 5% CO2. Cultures were utilized at 21 days in vitro 
(DIV) unless stated otherwise. 
 
Monocyte derived Macrophage (MDM) culture: HIVMDM supernatants were derived 
from monocyte-derived macrophage cultures infected with HIV-1 as described 
previously (Chen et al., 2002). HIV infection of macrophages was confirmed by serial 
quantification of p24 antigen levels in the culture supernatants over time and only 
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HIVMDM supernatants exhibiting productive infection (p24 levels greater than 100 
pg/ml of supernatant) were used to treat neuronal cultures. Supernatants from HIVMDM 
and non-infected macrophages (mock-infected MDM) were collected at selected time 
points after infection and stored at -80°C.  
 
Western blotting: Whole cell extracts were prepared from primary rat cortical cultures. 
Cells were lysed for 20min with ice-cold lysis buffer consisting of 50mM  Tris–HCl, 
150mM NaCl, 0.1% SDS, 0.1% IGEPAL, 0.5% sodium deoxycholate, and a protease 
inhibitor cocktail (Sigma). Lysates were centrifuged at 16,100 g, at 4°C for 10 minutes 
and supernatants were collected. Protein concentrations were determined by Bradford 
assay, 30μg of protein was loaded in each lane of a 4-12% Bis-Tris gradient gel for 
protein separation and subsequently transferred onto PVDF membranes. Routine 
immunoblotting and autoradiography procedures were followed as described (Akay et al., 
2011).  
 
Subcellular fractionation: Cytoplasmic and nuclear protein extractions were performed 
using Panomics’ Nuclear Extraction Kit (Panomics Inc.) following the manufacturer’s 
protocol. Briefly, cells were lysed with ice cold lysis buffer (10 mM HEPES pH 7.9, 
10mM KCl, 10 mM EDTA, 4% IGEPAL, 10mM DTT, protease inhibitor cocktail). 
Lysates were centrifuged at 16,100 g for 3 min and the supernatant (cytoplasmic fraction) 
was collected. The nuclear pellet was resuspended in buffer (20mM HEPES pH 7.9, 
0.4M NaCl, 1mM EDTA, 10% glycerol, 10mM DTT, protease inhibitor cocktail) and 
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incubated on a rocking platform at 4°C for 2 hours. Following centrifugation at 16,100 g 
for 5 min, the supernatant (nuclear extract) was collected. Protein (30μg) was resolved on 
a 4-12% gradient TBE gel and probed with antibodies against E2F1. 
 
In vitro calpain cleavage assay:  Primary rat cortical cultures were harvested using lysis 
buffer (137mM NaCl, 2mM EDTA, 10% Glycerol, 20mM Tris-HCl pH=8, 1% protease 
inhibitor cocktail). Resulting lysates were incubated with 2mM CaCl2 at 4°C for 6 hours 
in the presence or absence of 500nM of purified calpain-1 (EMD Millipore). The 
reactions were then terminated by SDS-PAGE sample buffer resolved on a 4-12% 
gradient Bis-Tris gel, followed by western blotting as described above. Calpain cleavage 
of affinity-purified FLAG/MAT-tagged E2F1 was performed using the above protocol 
with the following modifications: FLAG-transfected E2F1 protein was affinity-purified 
as indicated by manufacturer (Sigma). Prior to elution, FLAg-E2F1 was incubated at 4°C 
with 100ug neuronal protein lysate for 30 minutes followed by addition of calpain and 
CaCl2 as indicated above. 
 
Neurotoxicity assessment: Neurotoxicity was quantified by a MAP2 cell-based ELISA 
as described previously (Wang et al., 2007). In parallel cultures, blinded-hand counts of 
Propidium Iodide-excluded MAP2-positive cells were performed to assess neuronal death 
as described (Akay et al., 2011). 
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Statistical analysis: Values are expressed as mean ± SEM. Paired results were analyzed 
by Student’s t-test. Data with multiple categories were analyzed by one-way ANOVA 
followed by the Newman–Keuls post-hoc test using Prism software (GraphPad 
Software). Values of p < 0.05 were considered significant. 
 
3.4  RESULTS 
HIVMDM-induced neurotoxicity is attenuated in cortical neurons from E2F1 
mutant mice 
Increased E2F1 protein levels have previously been observed in post-mortem analysis 
from patients with HIVE (Jordan-Sciutto et al., 2002). We investigated the link between 
E2F1 and HIV-mediated neurodegeneration, employing an in vitro model of HIV-
induced neurotoxicity in which primary rat cortical neuroglial cultures are treated at DIV 
20 with conditioned media from HIV-infected human monocyte-derived macrophages 
(HIVMDM) (O'Donnell et al., 2006). In this model, neuronal death is dependent on 
NMDA receptor stimulation and calpain activation (O'Donnell et al., 2006). To assess the 
role of E2F1 in HIV-mediated neurotoxicity, we treated cortical cultures from E16 mouse 
embryos lacking functional E2F1 and from wildtype controls with either HIVMDM or 
Mock-infected macrophage supernatants (MOCK). Neuronal toxicity was assessed by 
cell-based ELISA for the dendritic marker MAP2 (Figure 3.1A) and confirmed through 
blinded hand-counts of MAP2-positive cells (Figure 3.1B). While HIVMDM 
supernatants cause dose-dependent neurotoxicity in wildtype cultures, E2F1 mutant 
cultures displayed lower levels of neurotoxicity relative to wildtype control cultures at all 
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but the most concentrated HIVMDM dose (Figure 3.1A, 3.1B). The reduced toxicity in 
neurons lacking functional E2F1 suggests that loss of E2F1 confers partial protection 
against HIV-induced neuronal damage. 
 
HIVMDM-treated rat cortical cultures display lower molecular weight E2F1 
We have previously shown that E2F1 expression is predominantly cytoplasmic in post-
mitotic neurons and that mRNA levels of E2F1 transcriptional targets remain unchanged 
in neurons following HIVMDM treatment (Wang et al., 2010).  To explore the role of 
E2F1 in HIV-mediated neurotoxicity, we treated primary neuroglial cultures from rat 
cortex at DIV21 with HIVMDM supernatants and assessed E2F1 levels in subcellular 
fractions via immunoblot. E2F1 was primarily in the GAPDH-positive cytosolic fraction 
of both untreated and HIVMDM-treated neuronal cultures and largely absent from the 
Lamin A/C-containing nuclear fractions (Figure 3.2B). While the subcellular distribution 
of E2F1 seemed unchanged following HIVMDM treatment, the cytosolic fraction from 
HIVMDM-treated cultures contained a lower molecular weight E2F1 immunoreactive 
band in place of the full length E2F1 found in untreated and mock-treated neuronal 
cultures (Figure 3.2B). This lower molecular weight E2F1 (LMW-E2F1) band migrates 
at an apparent molecular weight 5 kDa below the full sized band and displays a dose-
dependent accumulation during HIVMDM treatment, showing increased production with 
decreasing dilutions of HIVMDM supernatant treatment (Figure 3.2C). Furthermore, the 
LMW-E2F1 is detectable as early as 6 hours following initial treatment and accumulates 
over time (Figure 3.2D). These results suggest that neuronal E2F1 is cytoplasmic and 
changes in size in response to HIV-associated neurotoxins. 
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Production of LMW-E2F1 is mediated by NR2A/2B-containing NMDA Receptor 
stimulation 
Since NMDA receptor subunit expression is developmentally regulated, HIVMDM does 
not induce toxicity in neuronal cultures until DIV 14-21 when NR2B-containing receptor 
maturation occurs (Wang et al., 2007). Interestingly, production of LMW-E2F1 by 
HIVMDM treatment is not detectable until after neuronal cultures reach 2 weeks of age 
(Figure 3.2A) suggesting that LMW-E2F1 may be dependent on NMDA receptor 
(NMDAR) stimulation.  To investigate this possibility, we pretreated cortical cultures at 
DIV 21 with the NMDAR antagonist MK801 for 30 minutes prior to the addition of 
HIVMDM supernatant. Blocking NMDAR activation with MK801 eliminated the 
production of LMW-E2F1 following HIVMDM treatment (Figure 3.3A). Treatment of 
neurons with synthetic NMDAR agonist NMDA also led to the generation of LMW-
E2F1, confirming that LMW-E2F1 production is NMDAR-dependent (Figure 3.4C). To 
determine whether LMW-E2F1 production was similarly mediated by NR2B containing 
receptors, we pretreated neuronal cultures with antagonists to different NMDA receptor 
subtypes prior to incubation with HIVMDM supernatants. While Zinc (NR1/2A) and 
Ifenprodil (NR1/2B) failed to block HIVMDM-induced formation of LMW-E2F1, 
Conantokin-G (all NR2B-containing) inhibited LMW-E2F1 production (Figure 3.3C). 
These results demonstrate that LMW-E2F1 production is selectively dependent on 
NR2A/NR2B-containing NMDAR stimulation. 
 
LMW-E2F1 is a calpain cleavage product 
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Our in vitro model of HIV-induced neurotoxicity depends on NMDAR stimulation and 
also on activation of calpains, the calcium-sensitive cysteine proteases subsequently 
activated by NMDAR-dependent Ca
2+
 influx (O'Donnell et al., 2006, Wang et al., 2007, 
White et al., 2011). Calpain was activated in the present experiments as revealed by 
increased levels of calpain-cleaved αII-spectrin in HIVMDM-treated neurons (Figure 
3.4A). We therefore hypothesized that NMDAR-dependent production of LMW-E2F1 
results from proteolytic cleavage of E2F1 by calpain. To test the involvement of calpain, 
we pretreated neuronal cultures with the cell-permeable pharmacologic inhibitor 
MDL28170 (Calpain inhibitor III) prior to HIVMDM incubation and measured resulting 
LMW-E2F1 production by immunoblot. Pharmacologic inhibition of calpains prevented 
the production of LMW-E2F1 while preserving the full length form of E2F1 observed in 
untreated neuronal cultures, suggesting that LMW-E2F1 is dependent on calpain 
activation (Figure 3.4B). To validate E2F1 as a bona fide substrate of calpain, we 
performed an in vitro calpain cleavage assay on untreated neuronal protein lysates. 
Incubation of the lysates with calcium and calpain reproduced the LMW-E2F1 product 
observed in HIVMDM- and NMDA-treated neurons, (Figure 3.4C). To definitively 
show that E2F1 is cleaved directly by calpain rather than through an event downstream of 
calpain activity, we performed an in vitro cleavage assay on neuronal lysates as before, 
then inhibited calpain activity by adding MDL28170 to the cleavage reaction and 
subsequently incubated the reaction with recombinant FLAG-E2F1 protein.  While 
endogenous E2F1 was cleaved by initial incubation with calpain, calpain inhibition 
blocked cleavage of the subsequently added FLAG-E2F1, again suggesting that the effect 
of calpain on E2F1 is through direct cleavage (Figure 3.4D). Finally, we incubated 
 72 
 
recombinant 
35
S-labeled E2F1 with -calpain or m-calpain in the presence of calcium.  
E2F1 was cleaved by both calpains in a similar time course (Figure S1). Together, these 
results demonstrate that E2F1 is cleaved by calpain to a smaller stable isoform following 
HIVMDM treatment and NMDAR stimulation. 
 
Stabilized calpain-cleaved E2F1 is generated preferentially in neurons 
To determine whether calpain cleavage may play a role in other cell or tissue types, we 
performed in vitro calpain cleavage assays on lysates from several different types of 
cultured cells and determined how efficiently the stabilized E2F1 cleavage product 
accumulated. Interestingly, the E2F1 cleavage product was produced in a number of 
different neuronal cell types including primary rat cortical neurons, primary rat 
hippocampal neurons, and retinoic acid-differentiated SHSY5y neuroblastoma cells, but 
did not stably accumulate in non-neuronal cells such as HEK293 cells and 
undifferentiated SHSY5y cells (Figure 3.5A). We found similar results in mouse tissue 
homogenates, where cleaved E2F1 was stably produced in brain samples but not those of 
other organs (data not shown). These findings suggest that calpain cleavage of E2F1 into 
a stable isoform occurs preferentially in neurons.   Given that undifferentiated and 
differentiated SHSY5y cells exhibited different capacities for generating cleaved E2F1 
and that cleaved E2F1 production was only detected in HIVMDM-treated neuronal 
cultures at DIV 14 or later, we suspected that formation of the stabilized cleavage product 
may be influenced by neuronal maturation. To test this possibility, we performed in vitro 
calpain cleavage assays on protein lysates from rat primary cortical neurons at different 
ages in culture. Incubation of protein lysates with activated calpain produced the 
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stabilized E2F1 cleavage product at all culture ages tested (Figure 3.5B), suggesting that 
both immature and mature neurons have the capacity to generate the calpain cleavage 
product. Together, these results suggest that production and stabilization of calpain-
cleaved E2F1 occurs preferentially in cells of neuronal lineage. 
 
Stabilization of cleaved E2F1 is protein conformation-dependent 
To determine what factors may be responsible for stabilizing cleaved E2F1 in neurons, 
we first tested whether heat denaturation of the neuronal protein lysate affected the ability 
of activated calpain to produce the stabilized product. In vitro calpain cleavage assays 
were performed on boiled and unboiled neuronal protein lysates and assessed by 
immunoblot for presence of the stabilized E2F1 cleavage product. We found that cleaved 
E2F1 production was disrupted by heat denaturation of the lysate, even when purified, 
natively folded E2F1 was added to the boiled lysate prior to calpain incubation (Figure 
3.6A). This result suggests that native conformation of neuronal proteins is necessary for 
stabilizing the cleaved product, providing a potential explanation for how calpain-cleaved 
E2F1 is preferentially stabilized in neurons.  
A growing number of studies have demonstrated that the post-translational 
modifications, particularly phosphorylation, of calpain substrates or their binding partners 
can influence their ability to be cleaved by calpain (Huang et al., 1997, Bi et al., 2000, 
Nicolas et al., 2002, Qin et al., 2010). As E2F1 is both acetylated and phosphorylated in 
mitotic cells, we disrupted phosphorylation and acetylation of the neuronal protein lysates 
to determine whether these modifications might alter calpain processing of E2F1. To 
dephosphorylate neuronal proteins, lysates were incubated with lambda protein 
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phosphatase, a pan phosphatase with activity toward phosphorylated serine, threonine, 
and tyrosine residues, prior to incubation with activated calpain. While 
dephosphorylation activity was confirmed through a decrease in phospho-Akt levels, 
stabilized calpain-cleaved E2F1 was still produced in our in vitro calpain cleavage assay 
following phosphatase treatment (Figure 3.6B).  We similarly disrupted global 
acetylation levels in the neuronal lysates through inhibition of histone deacetylases 
(HDACs) with Trichostatin A, which inhibits class I and II HDACs. Despite observing 
decreased acetylated alpha-tubulin from Trichostatin A treatment, production of calpain-
cleaved E2F1 appeared unaffected (Figure 3.6C). We also inhibited class III HDACs 
(sirtuins) using Nicotinamide treatment. While Nicotinamide has effects on other targets, 
Nicontinamide-mediated sirtuin inhibition has frequently been confirmed through 
decreased Erk1/2 signaling (Li et al., 2008, Lee et al., 2011, Zhao et al., 2012). We did 
observe decreased levels of phospho-Erk1/2 following Nicotinamide treatment; however, 
as with trichostatin A treatment, we observed no significant effect on the stable 
production of cleaved E2F1 (Figure 3.6D). Similar results were also observed following 
deglycosylation of the neuronal lysates (data not shown). Together, these results suggest 
that post-translational modifications of the surrounding neuronal proteins may not be 
important for stabilizing the calpain-cleaved E2F1 product. 
 
Calpain cleaves E2F1 at the N- and C-terminus 
To better understand the kinetics of calpain cleavage of E2F1, we assessed E2F1 products 
produced by addition of calpain over time.  By performing a time course of our in vitro 
calpain cleavage assay, we were able to identify an intermediate E2F1 cleavage product 
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that was produced early on during calpain incubation (Figure 3.7A). This intermediate 
product was further processed to the final stabilized cleavage product observed in 
neurons following HIVMDM treatment, suggesting that calpain cleavage of E2F1 
involves at least two distinct cleavage events. Arresting calpain activity during this time 
course prevented further conversion of full-length E2F1 to the intermediate product and 
blocked production of the stabilized final product (Figure 3.7A’), further demonstrating 
that both the intermediate and final E2F1 products are directly produced by calpain 
cleavage. To identify where the E2F1 protein is cleaved by calpain, we made use of a 
construct encoding a dually epitope-tagged E2F1 protein with the FLAG-tag at the N-
terminus and a metal affinity (MAT)-tag at the C-terminus. We affinity-purified the E2F1 
protein from transfected HEK293 cells and with the protein still bound by the affinity 
resin, we then incubated the purified protein with neuronal protein lysate to reproduce the 
environment in which production of stabilized calpain-cleaved E2F1 is observed. 
Following incubation with activated calpain, we assessed which epitope tags were lost 
and retained in the eluted fraction by immunoblot analysis. We found that both FLAG 
and MAT tags were lost following calpain incubation (Figure 3.7B) supporting the 
concept of two distinct cleavage events at each terminus of E2F1.   
 
Presence of LMW-E2F1 in human fetal neurons  
The data from our in vitro model of HIV-mediated neurotoxicity firmly establishes that a 
calpain-cleaved E2F1 fragment accumulates in primary rodent neuronal cultures 
following HIVMDM treatment. To determine whether E2F1 in human neurons is 
similarly processed by calpain, we cultured human fetal neurons and performed an in 
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vitro calpain cleavage assay on the protein lysates obtained from these cells. As observed 
with primary rat neuronal cultures, activated calpain processed E2F1 from human 
neurons to a smaller, stable product (Figure 3.8A). This product matched the size of the 
calpain-cleaved E2F1 isoform from primary rat neurons, suggesting that E2F1 in human 
neurons displays the same capability to be processed to the smaller product. A smaller 
E2F1 isoform was also observed in protein lysates from human cortical autopsy tissue by 
immunoblot. Interestingly, several of the samples from HIV+ patients with minor 
cognitive motor disorder (MCMD) and with HIV-associated dementia (HAD) contained a 
lower molecular weight E2F1 band that was not found in a sample from an HIV+ 
neurocognitively normal patient (Figure S2).  Production of this lower band did not 
correlate with post-mortem interval (Pearson’s Correlation: r=-0.103, p=0.684) or 
diagnosis (Fisher’s Exact: p=0.571 for HAD, p=0.545 for MCMD, p=0.576 for 
HAD+MCMD). Together, these results provide evidence for the production of a calpain-
cleaved E2F1 isoform in human neurons. 
 
3.5  DISCUSSION 
Unlike other proteolytic systems such as lysosomes and the ubiquitin-proteasome, 
calpains do not simply breakdown their substrates. In many cases, calpain proteolytic 
processing leads to modulatory effects on substrate structure and function. Here, we 
present evidence supporting the involvement of E2F1 in HIV-induced neuronal death 
mediated by calpains. Using an in vitro model of HIV-induced neurotoxicity that is 
dependent on calpain activation, we have shown that cortical neurons lacking functional 
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E2F1 are less susceptible to neuronal death.  Additionally, we report that neuronal E2F1 
is cleaved by calpain to a stable 55 kiloDalton fragment following NR2B-dependent 
NMDA receptor stimulation.  This cleavage of E2F1 is protein conformation-dependent 
and involves at least two cleavage events, one at each terminus of the protein. 
Intriguingly, the stabilized E2F1 cleavage product is produced in postmitotic neurons of 
all ages, but fails to be stabilized in cycling cells. We have previously reported that 
neuronal E2F1 displays the ability to shuttle between the cytosol and nucleus, a result 
also observed in differentiated keratinocytes (Strachan et al., 2005, Ivanova et al., 2007). 
Despite its nuclear-cytoplasmic shuttling capability, our results and previously published 
studies indicate that E2F1 is predominantly cytoplasmic in postmitotic neurons, similar to 
the localization recently reported for E2F1 in fully differentiated oligodendrocytes 
(Figure 3.2A, 3.2B, 3.3A)(Wang et al., 2010, Magri et al., 2014). Furthermore, neuronal 
E2F1 appears to be retained in the cytosol of HIVMDM-treated neurons following 
cleavage by calpain (Figure 3.2A, 3.3A), suggesting that the functional implications of 
E2F1 cleavage are distinct from those of Beta-catenin or Cdk5. This observation is 
further supported by the reported cytosolic E2F1 staining in neurons from post-mortem 
brain tissue of patients with HIVE, AD, ALS and PD (Jordan-Sciutto et al., 2001, 
Ranganathan et al., 2001, Hoglinger et al., 2007).  Finally, our previous studies using this 
in vitro model have demonstrated that transcription of several E2F target genes remains 
unchanged in neurons following HIVMDM treatment (Wang et al., 2010). These 
observations all argue against a functional effect of E2F1 cleavage on its activity as a 
transcription factor.  Future studies to define the E2F1 protein sequence that is preserved 
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following cleavage may shed light on the role of this calpain-cleaved transcription factor 
when it is retained in the cytosol. 
 Determining cleavage sites within calpain substrates is often challenging given 
the poor understanding of how substrate specificity is achieved. While several studies 
have reported amino acid preferences for calpain activity based on analysis of published 
substrate cleavage sites, these preferences are often insufficient to correctly predict 
cleavage sites in novel calpain substrates (Tompa et al., 2004, DuVerle et al., 2011). 
Furthermore, calpain substrates are often cleaved in multiple places, compounding the 
difficulty of accurately defining the resulting fragment.  For example, the microtubule-
associated protein Tau is cleaved by calpain at a minimum of three internal sites, 
resulting in a stable 17-kilodalton fragment that has been reported to play a role in 
neurotoxicity (Park and Ferreira, 2005, Liu et al., 2011). Similarly, voltage-gated sodium 
channel NaV1.2 is cleaved by calpain in two regions of the alpha-subunit, producing 
channel fragments that display altered channel properties (von Reyn et al., 2009, von 
Reyn et al., 2012). Our data suggests a similar pattern of calpain processing for E2F1 in 
neurons. At least two cleavage events, one at the N-terminus and one at the C-terminus, 
are responsible for producing the stabilized E2F1 cleavage product (Figure 3.7). E2F1 
has a Cyclin A binding domain that begins nearly 70 amino acids into its N-terminus. In 
dividing cells, E2F1-Cyclin A binding through this domain helps regulate E2F1-DNA 
binding. However, given the cytosolic localization of E2F1 in mature neurons, it is 
unlikely that the domain serves the same function in this cellular context. Similarly, the 
C-terminus of E2F1 contains the transactivation domain along with the pRB pocket 
binding domain, which has been studied exclusively in the context of E2F1-mediated 
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transcription. While these sequences have well-characterized roles in cycling cells, it is 
unclear how they may function in the neuronal cytosol. To what extent either of these 
domains is affected by cleavage is also unknown. Based on our results, the E2F1 
cleavage product displays a 5-10 kDa reduction in apparent molecular weight suggesting 
a loss of 45-90 amino acids. Future efforts to define the calpain cleavage sites are 
necessary to determine the consequence of disrupting the N- and C-terminal domains. 
 Despite a growing list of calpain substrates that have recently been identified, the 
rules surrounding substrate recognition and sequence cleavage are yet to be fully 
elucidated. In this study, we identified a stabilized E2F1 isoform produced by calpain 
processing.  Intriguingly, we were unable to observe this stabilized product in cells other 
than neurons (Figure 3.4). To our knowledge, this is the first example of a calpain 
substrate exhibiting distinct processing patterns in different cell types. To understand how 
this could be achieved, we first tested whether the stabilized cleavage product was 
dependent on protein conformation (Figure 3.6A). We found that protein conformation 
was indeed critical for the stabilized accumulation of cleaved E2F1, suggesting that 
neuronal E2F1 may contain unique binding partners that protect regions of the protein 
from further degradation. Interestingly, the E2F1 protein sequence has a number of P-X-
X-P motifs known to bind Src homology 3 (SH3) domains (Alexandropoulos et al., 
1995). We have previously reported that neuronal E2F1 is enriched in synaptosomes and 
co-localizes with the synaptic scaffolding protein PSD-95, which contains a C-terminal 
SH3 domain (Ting et al., 2014). Exploring whether PSD-95 or other synaptic proteins 
may bind E2F1 through SH3 binding domains may provide further clarity on the 
dependence of calpain-cleaved E2F1 on protein conformation. In addition to examining 
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native protein structure, we also tested whether post-translational modifications such as 
phosphorylation and acetylation may play a role in modifying calpain activity toward 
E2F1 in different cellular environments (Figure 3.6B-6D). There are multiple examples 
showing calpain preferentially cleaving substrates based on their phosphorylation state. 
Notably, the tumor suppressor p53 is preferentially cleaved by calpain when 
phosphorylated at one of its serine residues in developing neurons (Qin et al., 2010). A 
separate study focusing on calpain-mediated cleavage of NMDA receptors found that 
tyrosine phosphorylation of NR2 subunits protected their C-terminal domains from 
calpain processing (Bi et al., 2000). Finally, αII-spectrin, one of the prototypical calpain 
substrates, also shows decreased sensitivity to calpain cleavage when phosphorylated at 
one of its tyrosine residues (Nicolas et al., 2002). While post-translational modifications 
to E2F1 have not been explored in neurons, we thought they may provide a basis for 
calpain to differentially process neuronal E2F1. Given the numerous instances when 
E2F1 is phosphorylated and acetylated in dividing cells, we attempted to 
pharmacologically disrupt both of these modification systems in neuronal lysates to 
determine whether calpain cleavage of E2F1 is altered. However, neither phosphatase 
treatment nor inhibition of HDACs or Sirtuins significantly affected the formation of the 
stabilized E2F1 calpain cleavage product (Figure 3.6). Whether other post-translational 
modifications are involved in directing calpain processing of E2F1 is still a possibility. A 
comprehensive understanding of neuronal E2F1 post-translational modifications will 
likely be necessary to fully explore this issue. 
Our findings suggest that calpain cleavage of E2F1 occurs during a neurotoxic 
event and contributes to this process as we have observed reduced neurotoxicity in 
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HIVMDM-treated cortical neurons lacking functional E2F1 (Figure 3.1). Interestingly, 
we were able to completely block calpain cleavage of E2F1 using the NR2B subunit 
inhibitor Conantokin G, suggesting that cleaved E2F1 requires NR2B-NMDAR 
stimulation (Figure 3.3B). A recent study detailed how synaptic NMDAR stimulation 
leads to μ-Calpain activation and subsequent neuroprotection, while extrasynaptic 
NMDAR stimulation leads to m-Calpain activation that promotes neurotoxicity (Wang et 
al., 2013). A study that deleted both μ-Calpain and m-Calpain in the CNS of mice define 
roles for these proteases in both excitotoxic death and synaptic plasticity (Amini et al., 
2013). Given that NR2B subunits are typically found at extrasynaptic locations, the 
NR2B-dependent nature of E2F1 processing by calpain suggests that it requires 
extrasynaptic NMDAR activity and subsequent neurotoxic activation of m-calpain. 
Although the NR2B-dependent nature of E2F1 processing suggests that it is part of a 
neurotoxic pathway, it is important to note that both m-calpain and μ-calpain are able to 
proteolytically cleave E2F1 (Figure S1), and that calpain-cleaved E2F1 may fulfill a 
neuroprotective function either in our model of HIV-induced neurotoxicity or possibly in 
other neuronal contexts such as development. Indeed, we have shown that calpain-
cleaved E2F1 can be produced in immature neurons that have not yet expressed NR2B 
subunits (Figure 3.5B), suggesting the possibility of a role in synaptic development. It 
should also be noted that the attenuated HIVMDM-induced neurotoxicity observed in 
E2F1 mutant neurons could be due to a loss of physiologic E2F1 function rather than 
absence of a gain-of-toxic function in wildtype cultures. While it seems unlikely that 
E2F1 in the cytosol could promote neurotoxicity by activating transcription of apoptotic 
genes, it is quite possible that it could influence calcium homeostasis. Previous work 
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from our lab has shown that overexpression of a transcriptionally inactive N-terminally 
truncated E2F1 protein in HEK293 cells causes calpain-dependent cell death (Strachan et 
al., 2005). Interestingly, this truncated E2F1 product is cytoplasmic much like the 
neuronal E2F1 protein that we detect in primary neuronal cultures. While these results 
were obtained from cell lines, they provide an intriguing comparator to calpain-cleaved 
neuronal E2F1 and suggest the possibility that the E2F1 cleavage product may serve to 
amplify calpain activation. In fact, a number of calpain substrates have been reported to 
perform this function, promoting further cytosolic calcium increases upon cleavage. For 
instance, the Type 1 IP3 receptor, which functions as an ER calcium channel, disrupts 
intracellular Ca
2+
 buffering when cleaved by calpain (Kopil et al., 2012). Similarly, L-
type Calcium channels in cultured neurons are cleaved by calpain, leading to C-terminal 
truncation of their α1 pore-forming subunit and enhanced Ca
2+
 influx from the L-type 
channels (Klockner et al., 1995, Hell et al., 1996). Cleavage of these substrates and others 
help create a positive feed-forward pathway that further increases intracellular calcium 
levels, thereby amplifying calpain activation. Our results showing the presence of a lower 
molecular weight E2F1 band in a subset of subcortical tissue samples from patients with 
HAND may similarly be due to intracellular calcium dysregulation (Figure S2) and 
additional studies with greater statistical power are warranted. Interestingly, neuronal 
E2F1 has been reported to bind Necdin, a factor involved in maintaining the terminally 
differentiated identity of postmitotic neurons (Kuwako et al., 2004). Further, Necdin has 
been linked to intracellular calcium regulation through its interaction with NEFA, a 
calcium-binding protein located on the ER cisternae which regulates ER calcium release 
(Taniguchi et al., 2000). As Necdin interacts with the C-terminal domain of E2F1, further 
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work to determine if calpain-cleaved E2F1 could participate in calcium regulation 
through changing its interaction with Necdin and NEFA would provide further insight 
into this pathway. 
Our findings indicate that E2F1 exhibits novel regulation by calpain cleavage in 
neurons.  Further, cleavage of E2F1 by calpain is independent of known phosphorylation 
and acetylation events and appears to be dependent on an interacting protein partner.  
Finally, an isoform of E2F1 with similar size to calpain-cleaved E2F1 is apparent in 
cortex from HIV-infected patients with cognitive deficits while it is absent in cognitively 
normal patients.  Understanding the role of this stabilized calpain cleavage project will 
provide novel therapeutic implications for treating patients with cognitive decline linked 
to excititoxic injury including HAND, AD, ALS and PD.   
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Figure 3.1. HIVMDM-induced neurotoxicity is attenuated in cortical neurons from 
E2F1 mutant mice. a. Cortical neurons from wild type (black bars) and E2F1 mutant 
mice (white bars) at DIV 20 were treated with HIVMDM supernatants or Mock-MDM 
supernatants at indicated dilutions for 20 hours. Resulting neuronal damage was 
measured by a cell-based MAP2 ELISA (*** denotes p<0.01) (White et al., 2011). b. 
Blinded hand counts of MAP2-positive, propidium iodide-negative cells from wildtype 
(square) and E2F1 mutant (triangle) cortical cultures treated with indicated dilutions of 
HIVMDM (black) and mock (white) supernatants for 20 hours (*denotes p<0.05). 
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Figure 3.2. HIVMDM-treated rat cortical cultures display lower molecular weight 
E2F1 (LMW-E2F1). a,b. Immunoblot analysis of LaminA/C-positive nuclear fraction 
and GAPDH-positive cytoplasmic fraction from rat cortical cultures at DIV14 (a) and 
DIV21 (b) following 20-hour HIVMDM or Mock treatment. c. Immunoblot analysis of 
E2F1 from GAPDH-positive, LaminA/C-negative cytosolic fractions of rat cortical 
cultures (DIV21) treated with indicated dilutions of HIVMDM for 20 hours. Coomassie 
gel stain used for loading control (a, b, c). d. E2F1 immunoblot analysis of rat cortical 
cultures at DIV 21 following a time-course of HIVMDM or Mock treatment (Actin: 
loading control). 
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Figure 3.3. Production of LMW-E2F1 is mediated by NR2A/2B-containing NMDAR 
stimulation. a. Immunoblot of subcellular fractions from rat cortical cultures (DIV21) 
treated for 20 hours with HIVMDM or mock supernatants. For indicated samples, 
NMDAR antagonist MK801 (10µM) was added to cultures 30 minutes prior to 
supernatant treatment. Coomassie-stained gel serves as a loading control. b,c. Rat cortical 
cultures at DIV21 were pre-treated for 1 hour with different NMDAR subunit inhibitors 
(Table, c) followed by HIVMDM treatment. Conantokin G (CoG, 10μM), which blocks 
NR2A/2B-containing NMDARs prevented the production of LMW-E2F1, while 
Ifenprodil (Ifn, 10μM), which blocks NR2B/2B-containing NMDARs, and Zinc (Zn, 
500nM) which blocks NR2A-containing NMDARs, had no effect on HIVMDM-induced 
formation of LMW-E2F1. Coomassie-stained gel serves as a loading control. 
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Figure 3.4. LMW-E2F1 is a calpain cleavage product. a. Samples from primary rat 
cortical cultures at DIV21 were immunoblotted for calpain-cleaved aII-spectrin to 
measure calpain activation following HIVMDM treatment. Coomassie gel stain serves as 
a loading control. b. To block calpain activation, cortical cultures were pretreated with 
calpain inhibitor MDL28170 (20uM) for 30 minutes prior to HIVMDM. Coomassie gel 
stain serves as a loading control. c. In vitro calpain cleavage assay of neuronal lysates 
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from untreated cultures at DIV 21 with calpain-1 (10ug/mL) and 2mM CaCl2. Reaction 
mixture was incubated at 4°C for 6 hours. Untreated lysate from untreated and NMDA-
treated cultures serve as controls for full length and LMW-E2F1 (top and bottom 
arrowheads, respectively). d. In vitro calpain cleavage assay to test direct cleavage of 
E2F1 by calpain. Addition of MDL28170 to neuronal lysates prior to incubation with 
calpain-1 and CaCl2 blocked formation of LMW-E2F1 (pre-MDL). Following 4 hours of 
the 6-hour incubation of neuronal lysate with calpain-1, MDL28170 was added along 
with affinity-purified FLAG-E2F1 to the reaction (post-MDL and post-FLAG-E2F1, 
respectively) to determine whether exogenous E2F1 is protected by calpain inhibition 
following cleavage of endogenous targets.  
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Figure 3.5. Stabilized calpain-cleaved E2F1 is generated preferentially in neurons. a. 
In vitro calpain cleavage assays were performed on protein lysates from indicated cell 
types to assess the influence of cell type on production of stabilized calpain-cleaved 
E2F1.  Lysates were collected from primary rat cortical and hippocampal cultures at 
DIV21, and from differentiated SHSY5y neuroblastoma cells following 10-day retinoic 
acid treatment. b. In vitro calpain cleavage assay of lysates from primary rat cortical 
neurons at indicated ages in culture.  
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Figure 3.6. Stabilization of cleaved E2F1 is protein conformation-dependent. a. In 
vitro calpain cleavage assays were performed on rat cortical neuronal lysates from 
cultures at DIV21 that were boiled or unboiled. Purified FLAG-E2F1 protein that was 
added to the boiled lysate failed to show stable accumulation of cleaved E2F1 when 
incubated with calpain-1. FLAG-MAPK served as a control to demonstrate calpain 
substrate specificity in the assay. b. To determine the effect of protein phosphorylation on 
the stabilization of calpain-cleaved E2F1, neuronal lysate (05μg/μL) was treated with λ 
protein phosphatase (λPP, 600 units) for 1 hour at 25°C prior to incubation with calpain-1 
and CaCl2 at 4°C. Phospho-Akt levels normalized to total Akt levels were measured to 
confirm effect of λPP treatment. c,d. Rat cortical cultures were treated for 24 hours with 
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either 1μM Trichostatin A (TSA) to inhibit class I and II HDACs (c) or Nicotinamide 
(low=1μM, high=25μM) to inhibit class III HDACs (d). Cultures were harvested and 
total protein lysates were subjected to in vitro calpain cleavage assay. HDAC inhibition 
was confirmed by increased levels of acetylated α-tubulin over total α-tubulin and 
decreased levels of phospho-Erk1/2 over total ERK.  
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Figure 3.7. Calpain cleaves E2F1 at N- and C-terminus. a. Time course of in vitro 
calpain cleavage assay was performed on lysates from rat cortical cultures for indicated 
times. Samples were run on a 10% Bis-Tris polyacrylamide gel to better resolve 
molecular weight differences of E2F1 bands due to calpain processing. Samples from 
early time points show generation of an intermediate product (middle arrow) before 
complete conversion to the stabilized calpain-cleaved E2F1 product (bottom arrow). 
Lysate from NMDA-treated cultures served as a positive control for calpain-cleaved 
E2F1. Calpain-cleaved αII-spectrin shows progressive calpain activity over time course. 
a’. Time course of calpain cleavage assay was performed as in (a) but with addition of 
MDL28170 (20uM) beginning at t=20 minutes to inhibit calpain activity at all subsequent 
time points. b. Differentially epitope-tagged FLAG-E2F1-MAT overexpressed in 
HEK293 cells was affinity purified with either FLAG antibody or Nickel resin. Purified 
protein was incubated with neuronal lysate (50ug) for 30 minutes while still resin-bound 
prior to performing an in vitro calpain cleavage assay and subsequent elution. Eluted 
protein was assessed for presence of N-terminal FLAG tag and C-terminal MAT tag by 
immunoblot analysis. FLAG-MAPK-MAT served as a control to demonstrate E2F1-
specific calpain processing and as a positive control along with FLAG-BAP for 
successful purification.  
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Figure 3.8. Lower molecular weight E2F1 is produced in in human fetal neurons. 
Protein lysates from cultured human fetal neurons (HFN) at DIV 17 were subjected to an 
in vitro calpain cleavage assay as described above. Immunoblot analysis of resulting 
samples assessed levels of E2F1 and calpain-cleaved αII-spectrin to measure calpain 
activation. Lysate from NMDA-treated rat cortical cultures (RCN) served as a positive 
control for calpain-cleaved E2F1.  
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3.7  SUPPLEMENTAL DATA 
E2F1 in neurons is cleaved by calpain in an NMDA receptor-dependent manner in a 
model of HIV-induced neurotoxicity 
 
 
Figure S1. Proteolytic processing of E2F1 by Calpain-1 and Calpain-2. In vitro 
translated full-length E2F1 (2 μg) was incubated with recombinant μ- or m-calpain for 
indicated times in the presence of 0.1mM or 1mM CaCl2, respectively. The reaction 
mixtures were then resolved on a 4-12% gradient gel. The cleavage of E2F1 was 
visualized by SDS-PAGE on a 4-12% gradient gel using Coomassie Blue staining. 
Arrows denote transiently produced cleavage products. 
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Figure S2. Lower molecular weight E2F1 is observed in prefrontal cortex of HIV+ 
patients. E2F1 expression in autopsy brain tissue from HIV-positive patients was 
measured by immunoblot analysis. Whole cell protein extracts from mid-frontal cortex 
show a lower molecular weight E2F1 band (arrow) similar to the stabilized calpain-
cleaved E2F1 product observed in HIVMDM-treated neuronal cultures. Actin levels 
serve as a gel loading control. 
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Table S1 Summary of case data for autopsy tissue obtained from the NNTC 
Case HIV  Gender Age 
(years) 
PMI (hr) NeuroCog Neuropath 
Dx 
HAD1 + M 35 9.25 HAD Not HIVE 
HAD2 + F 34 5 HAD Not HIVE 
HAD3 + M 57 5.5 HAD Not HIVE 
HAD4 + M 32 14.5 HAD HIVE 
HAD5 + M 38 5.5 HAD HIVE 
HAD6 + M 32 14 HAD HIVE 
MCMD1 + M 36 2.5 MCMD Not HIVE 
MCMD2 + M 37 11.5 MCMD Not HIVE 
MCMD3 + M 31 8.83 MCMD Not HIVE 
MCMD4 + M 49 67.33 MCMD Not HIVE 
MCMD5 + M 42 27.33 MCMD Not HIVE 
MCMD6 + M 50 21 MCMD HIVE 
MCMD7 + M 43 unknown MCMD HIVE 
NORMAL + M 50 18 Normal Not HIVE 
CONTROL1 - M 46 27.65 ND Control 
CONTROL2 - F 47 19.2 ND Control 
CONTROL3 - M 40 14.66 ND Control 
CONTROL4 - F 51 21.75 ND Control 
 
Table S1. Data on the HIV status, gender, age in years, post-mortem interval (PMI) in 
hours, neurocognitive diagnosis (NeuroCog), and neuropathologic diagnosis (Neuropath 
Dx) are summarized. Abbreviations: F, female; HAD, HIV-associated dementia; HIVE, 
human immunodeficiency virus encephalitis; M, Male; MCMD, minor cognitive motor 
disorder; ND, not determined; NNTC, National NeuroAIDS Tissue Consortium; PMI, 
postmortem interval. 
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METHODS 
 
In vitro translation of E2F1 
In vitro translated 
35
S-labeled full-length E2F1 (2μg) was incubated with recombinant μ- 
or m-calpain, (Calbiochem), in a reaction buffer containing 50mM HEPES buffer (pH 
7.4), 150mM NaCl, 1mM EDTA, and 1% Triton X-100. Calpain was activated with 0.1 
or 1mM CaCl2, and reactions were incubated at 4°C for indicated times and then 
terminated by SDS-PAGE sample buffer. The reaction mixtures were then resolved on a 
4-12% gradient gel. The cleavage of E2F1 was visualized using Coomassie Blue 
staining of the gel. 
 
Western blotting of human brain tissue 
 Frozen tissue samples from midfrontal cortex of HAD (n = 6), MCMD (n = 7), and 
control (n = 5) human autopsy cases were obtained from the tissue banks of National 
NeuroAIDS Tissue Consortium (Morgello et al. 2001). Due to limited availability, 
cortical tissue from only one HIV-infected, cognitively normal case was obtained. Donor 
demographics are listed in Table 1. For protein extraction, tissue was homogenized and 
prepared for immunoblot as described (Akay et al. 2012). 100 μg of protein was loaded 
per lane on a 10% Bis-Tris gel, followed by standard immunoblotting techniques 
described under Western blotting in Materials and Methods. 
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CHAPTER 4 
Investingating the RNA binding domain of E2F1: Preliminary Studies for 
cytosolic E2F1 functions  
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4.1  ABSTRACT 
In addition to its well-known role as a transcription factor in cell proliferation, E2F1 
has been linked to neuronal death in neurodegenerative diseases such as Alzheimer 
Disease, Parkinson’s Disease, and HIV Encephalitis. Interestingly, E2F1 is localized 
predominantly in the cytosol of post-mitotic neurons, a striking finding given its 
nuclear localization in cycling cells. Previous work has shown that E2F1 binds to 
synthetic RNA species containing a specific stem loop secondary structure and that 
E2F1 can bind RNA from cortex, a capability that requires its DNA-binding domain. 
These findings led us to hypothesize that E2F1 may play a role in neuronal survival 
during neurodegenerative disease by regulating RNA through direct binding. By using 
site-directed mutagenesis, electrophoretic mobility shift assays (EMSA), and 
immunoprecipitation, we conducted a preliminary investigation of the requirement of 
specific amino acids in the DNA binding domain of E2F1 for RNA binding. Our 
analysis identifies amino acid R125 and N152 as sites of interest for distinguishing 
RNA binding and DNA binding capabilities. More work is needed to define the E2F1 
RNA binding domain 
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4.2  INTRODUCTION 
E2F1 is one of 9 members of the E2F family of transcription factors. Traditionally, 
increased transcriptional activity of the E2F proteins leads to the expression of gene 
products necessary for DNA synthesis and progression to S-phase. E2F1 is considered 
an E2F ‘activator,’ which refers to its ability to transcriptionally upregulate 
transcription of its gene targets. E2F1 is predominantly regulated by interactions with 
transcription factor DP1 and tumor suppressor Retinoblastoma protein (pRB). 
Heterodimerization of E2F1 with DP1 and hyperphosphorylation of pRB (ppRB) both 
lead to enhancement of E2F1 nuclear activity (Bandara et al., 1993, Nicolay and 
Dyson, 2013).  
In addition to its role in cell division, E2F1 has been implicated in cell death 
through its transcriptional activation of a number of genes in the apoptotic cascade. 
Multiple studies have demonstrated that activation of E2F1 by phosphorylation of 
pRb is necessary and sufficient for neuronal cell death in vitro (Giovanni et al., 1999, 
Park et al., 2000). E2F1 levels as well as ppRb levels increase in neurons during 
neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s disease and HIV 
encephalitis (Jordan-Sciutto et al., 2002a, Jordan-Sciutto et al., 2002b, Hoglinger et 
al., 2007). Interestingly, it has been observed that E2F1 is predominantly cytoplasmic 
in post-mitotic neurons both in culture and in post-mortem brain tissue from patients 
with Alzheimers Disease and HIV Encephalitis (Jordan-Sciutto et al., 2002b, Strachan 
et al., 2005), suggesting that E2F1 may carry out a neuronal function independent of 
its role as a transcription factor. 
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 E2F1 belongs to a superfamily of DNA binding proteins that contain winged-
helix DNA binding domains (Zheng et al., 1999). A number of proteins in this 
superfamily, including the Lupus La protein and SelB, have shown the ability to bind 
RNA in addition to DNA (Dong et al., 2004, Yoshizawa et al., 2005). Furthermore, a 
previous study reported that E2F1 could bind several synthetic RNA species in vitro. 
One of these species contains a stem loop secondary structure (Figure 4.1) that was 
shown to be critical for E2F1 binding (Ishizaki et al., 1996). Work by others in our lab 
has shown that E2F1 can bind RNA from tissue. To determine if E2F1 can bind 
endogenous RNA, GST-tagged E2F1 protein was incubated with RNA isolated from 
human cortex and then pulled down using a Glutathione Sepharose affinity column. 
RNA bound to affinity-purified E2F1 containing the full length sequence but not to 
E2F1 lacking the DNA binding domain, suggesting that E2F1 can bind cellular RNA 
from neurons and that this interaction requires the DNA binding domain 
(unpublished, A. Barnstable). Finally, RNA isolated from cultured SHSY5y 
neuroblastoma cell lines were similarly shown to bind E2F1 using a formaldehyde 
crosslinking assay (not shown). 
 
 
 
 
 
 
Figure 4.1 E1 ligand secondary structure. Stem loop secondary structure of E1 
RNA, ligand that has been shown to bind efficiently to E2F1 (Ishizaki et al., 1996). 
The C1 stem loop is denoted in the box  
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Given the above observations that E2F1 is predominantly cytoplasmic in 
post-mototic neurons and capable of binding RNA, we hypothesized that neuronal 
E2F1 may serve to regulate RNA transcripts through direct binding of cytosolic RNA 
species. To investigate the RNA binding motif of E2F1, we introduced point 
mutations to a number of different amino acid residues in the DNA binding domain of 
E2F1 that have previously been shown to contact DNA in an E2F:DP:DNA complex 
(Zheng et al., 1999). The wildtype and point mutation-containing constructs were then 
cloned into FLAG-tagging vectors with the goal of overexpressing these E2F1 
variants in cell lines and assessing their relative affinity for DNA and RNA using 
Electrophoretic Mobility Shift Assays (EMSA). In experiments using cell extracts, 
supershifts using FLAG antibody were performed to verify the identity of the DNA-
bound protein. Furthermore, purified DP1 was prepared and added to the EMSA 
samples during the incubation step to make the comparison of E2F1:DNA and RNA 
binding assays physiologically relevant, 
 
4.3  METHODS 
Site-Directed Mutagenesis  
To introduce point mutations to strategic residues in the DNA binding domain of 
E2F1, we used Stratagene's QuikChange™ XL Site-Directed Mutagenesis Kit. 
Mutagenesis primer pairs for each intended point mutations were designed by 
following the primer design guideline in the protocol prior to performing mutagenesis 
reactions. Mutagenesis reactions were performed according to the manufacturer’s 
instructions with commercially-ordered DNA primers purified by standard desalting. 
For each mutagenesis reaction 10ng of template DNA (FLAG-rE2F1 – a plasmid 
encoding rat E2F1 with an N-terminal FLAG-tag and C-terminal metal affinity tag) 
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Following the PCR mutagenesis reaction, methylated and hemimethylated DNA was 
selectively digest by incubating the reaction with Dpn I to remove any remnants of the 
parental DNA and to enhance selection for point mutant clones. Bacterial 
transformations were performed with XL10-Gold Ultracompetent Baterial cells as 
indicated in the instructions. Selection on LB-kanamycin agar plates was then 
performed and DNA was purified from resulting transformants and sequenced to 
confirm successful mutagenesis.  
  
3' End DNA Biotinylation 
By using Thermo Scientific's Biotin 3´ End DNA Labeling Kit, we were able to 
effectively create 3' end biotin-labeled double-stranded DHFR DNA, which has been 
shown to bind E2F1. 25 μl of ddH2O, 5 μl of 5x Tdt reaction buffer, 5 μl of unlabeled 
oligo (control or forward/reverse strand of DHFR, 100nM final concentration), 5 μl of 
Biotin-11-UTP (0.5 μM final concentration), and 10 U of diluted Tdt were mixed and 
incubated for 30 minutes at 37°C. Then, 2.5 μl of 0.2M EDTA and 50 μl chloroform: 
isoamyl alchohol were added to terminate each reaction and to extract excess Tdt. The 
remaining samples were vortexed and centrifuged at high speed to separate out 
phases, conserving the resulting top aqueous layers. Finally, the forward and reverse 
strands of DFHR were annealed to form double stranded DNA by combining the two 
samples and incubating at room temperature for 1 hour. 
 
Electrophoretic Mobility Shift Assay (EMSA)  
EMSA experiments in this study were conducted using an EMSA Assay Kit from 
Signosis. First, cell extracts of neurons (magnet-assisted transfection) and HEK 293 
(Lipofectamine transfection) were collected in whole cell lysis buffer. DNA/RNA 
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competition and supershift reactions were then prepared by combining 5 μg of protein 
extract, 1 μl of poly d(I-C),  2.0 μl of 5x Binding buffer, and ddH2O to create 10 μl  
total volume reaction samples. The samples were incubated on ice for 5 minutes. 
Then, 1.0 μl of either cold probe of varying concentrations (10ng, 100ng and 1000ng 
for DNA cold probe, and 10ng, 50ng, and 200ng for RNA cold probe) for competition 
assays, or FLAB antibody for supershift assays, was added to the samples. Additional 
incubation on ice for 20 minutes was made.  Finally, 2 μl of biotin labeled DHFR hot 
probe was added to each sample, and further incubated for 1 hour at room 
temperature.  
 6.5% non-denaturing polyacrylamide gels were cast and used to run the EMSA 
samples. Gels were run at 100V for 90 minutes at 4°C following a 30 minute pre-run, 
and transferred on to a nylon membrane at 40V for 150 minutes at 4°C. UV 
crosslinking was performed to capture protein-nucleic acid complexes on the 
membrane. The membrane was then blocked, incubated with Streptavidin-HRP, and 
washed before visualizing nucleic acid probes by chemiluminescence. 
 
Immunoprecipitation 
As mentioned above, overexpressed FLAG-DP1 proteins in HEK 293 cells were 
purified using FLAG Immunoprecipitation Kit produced by Sigma-Aldrich. 40 μl of 
ANTI-FLAG M2 affinity gel resin was aliquoted after thorough suspension. This was 
briefly centrifuged at 6,000 x g and resulting supernatant was removed. The 
remaining beads were wash with 1x FLAG Wash Buffer 3 times. Then, cleared HEK 
293 lysate containing overexpressed FLAG-DP1 proteins was added and incubated at 
4°C for 12 hours. After the incubation, the sample was centrifuged and aspirated to 
remove supernatant, leaving only the FLAG-DP1 bound beads. FLAG-DP1 proteins 
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were eluted from the beads by incubating in 115 μl of 3x FLAG Elution Buffer (15 μl 
of 3x FLAG peptide in 100 μl of 1x Wash Buffer). FLAG-BAP was similarly 
immunoprecipitated as a positive control. 
 
 
4.4  RESULTS AND DISCUSSION 
Previous work in the lab has shown that E2F1 is capable of binding cellular RNA 
from Rat cortex and that this ability is dependent on the E2F1 DNA binding domain. 
Additionally, E2F1 localization in neurons has been demonstrated to be 
predominantly cytoplasmic. These observations suggest that E2F1 may serve as an 
RNA binding protein in neurons. To better understand the RNA binding capability of 
E2F1, we sought to define its RNA binding domain. Since the DNA binding domain 
of E2F1 was necessary for binding cellular RNA, we reasoned that the RNA binding 
domain likely overlaps with the DNA binding domain. We therefore utilized an 
approach relying on site-directed mutagenesis of amino acid residues in the E2F1 
DNA binding domain known to play a role in DNA binding in order to assess the 
effect of the mutations on the relative binding affinity for DNA and RNA using 
EMSA competition assays. E2F1 amino acids R163, R164, and Y166 directly contact 
cysteine and guanine residues during DNA binding, and are likely necessary for direct 
binding to RNA as well. Therefore, conservative point mutations changing each of 
these residues to alanine were made to test their effects on E2F1:DNA and E2F1:RNA 
interactions. In addition, N152 in E2F1 corresponds to a lysine (K) in the DNA bindin 
domain of E2F4, which is exclusively nuclear in neurons. To test whether this amino 
acid confers E2F1 with a selective ability to bind RNA, N152 was mutated to lysine, 
the residue that E2F4 has at that position. N170, a neutral amino acid that binds to the 
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backbone of DNA, was mutated to A170 to see if it affects E2F1 RNA binding. 
Amino acids K180 and N184 have been shown to be in direct contact with DNA in a 
E2F1:DNA complex; therefore, point mutations changing both these amino acids to 
alanine(K180A and N184A) were made. Finally, R125, which contacts thymidine 
during DNA binding, was mutated to A to test the effect of this residue on the 
preference of E2F1 for DNA or RNA. Point mutations were performed using site-
directed mutagenesis primers and successful mutants were confirmed by sequencing 
of the DNA of resulting clones. We then analyzed expression of the cloned mutant 
constructs by transfecting HEK293 cells and measuring overexpression by Western 
Blot analysis (Figure 4.2). 
Prior to assessing the effect of each of these point mutants on DNA and RNA 
binding affinity, we set out to determine whether E2F1 displays different relative 
affinities for DNA and RNA binding depending on the cell type in which E2F1 is 
expressed. Since E2F1 localization is mainly cytoplasmic in neurons and nuclear in 
dividing cells, it is possible that these different subcellular localizations reflect 
different E2F1 RNA binding and DNA binding affinities. To begin testing this 
possibility, we overexpressed a truncated form of E2F1 missing the last 40 amino 
acids at the C-terminus in cultured rat cortical neurons. Protein lysates from 
transfected cultures were then used for EMSA assays using a biotin-labeled DNA 
probe from the Dhfr gene to detect E2F1-DNA complex formation. Increasing 
concentrations of unlabeled DNA probe and unlabeled E1 RNA ligand were used in a 
competition assay similar to those previously described to assess relative DNA and 
RNA binding (Ryder et al., 2008; Jordan-Sciutto et al., 1999). 
The EMSA analysis from these neuronal protein lysates demonstrates that both 
DNA and RNA show ability to compete for E2F1 binding (Figure 4.3). However, 
 115 
 
densitometry analysis of the EMSA image suggests that E2F1 has a higher affinity for 
RNA than for DNA, a result consistent with previously reported observations in cell-
free systems (Ishizaki et al., 1996). In the densitometry plot, the intensity of 
chemiluminescence was plotted against the amount of unlabeled competition species 
(DNA and RNA). Resulting slope of each linear regression trend line shows a steeper 
slope for the E1 RNA competitive inhibitor and therefore a higher affinity for RNA 
binding than DNA binding in neurons. It is also worth noting that a robust gel shift 
can be detected in untransfected neuronal lysates, suggesting that the observed gel 
shift is partially attributed to endogenous protein and that E2F1 may not be optimally 
overexpressed to obtain reliable data for cross-lane comparisons (lane 2 of Figure 
4.3a) 
 Although one of our ultimate goals is to compare E2F1-nucleic acid binding 
affinities in neurons and dividing cells, analysis of both the point mutant and wildtype 
E2F1 proteins would be more reliable in dividing cells where E2F1 overexpression is 
more robust. Various point mutation-containing E2F1 and wildtype constructs were 
overexpressed in HEK 293 cells and used in EMSA competition assays to assess their 
basal DNA binding level and the effectiveness of the unlabeled DNA probe to 
compete away this binding. Specifically, wildtype, R125A, L130A, N152K, and 
N170A constructs were tested in this experiment. Interestingly, R125A, which alters 
the thymidine binding residue, and N152K, which mirrors the E2F4 sequence at this 
residue, both show an inability to bind DNA regardless of the presence of cold 
competitor. The inability of R125A to bind DNA is consistent with the previous 
finding that human E2F1 R127S (the corresponding amino acid position in the human 
protein) showed an inability to bind DNA (Jordan-Sciutto et al. 1994), and suggests 
that this residue is critical for DNA binding (Figure 4.4). The inability of N152K to 
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produce a gel shift is surprising given that E2F4 contains this point mutation in an 
otherwise highly conserved E2F DNA binding domain and is capable of binding DNA. 
On the other hand, wildtype E2F1 displayed DNA binding that was clearly detectable 
by EMSA and efficiently competed away by cold DNA competitor (Figure 4.4). E2F1 
N170A similarly showed an ability to bind DNA despite the point mutation, 
suggesting that altering this residue is not sufficient to significantly disrupt 
E2F1:DNA binding. 
In order to increase sensitivity of E2F1:DNA binding in our EMSA assay and 
ensure that the lack of gel shifts observed is indeed due to a lack of DNA binding, we 
decided to introduce increased amounts of the E2F1 DNA binding cofactor DP1 in the 
EMSA reactions. Since E2F1 affinity for DNA is dramatically enhanced when 
heterodimerized with DP1, we hypothesized that increased presence of DP1 would 
enhance E2F1 affinity for DNA. To do so, HEK 293 lysates were transfected with 
FLAG-DP1-myc transfection with and without FLAG-rE2F1 co-transfection and 
overexpression was confirmed using Western Blot analysis (Figure 4.5, Top left 
panel). Successful overexpression was demonstrated using antibodies to DP1, FLAG 
and myc. Although DP1 overexpression was observed while co-transfecting HEK293 
cells with FLAG-E2F1, it was not as robust as when DP1 was overexpressed on its 
own. To maximize the amount of DP1 added to the reaction, we decided to purify 
DP1 protein from the single transfection HEK lysates by FLAG affinity purification 
(Figure 4.5, Top right panel). Following affinity purification, DP1 was added to the 
EMSA reactions to determine whether it could amplify the gel shift signal. In 
addition, EMSA reaction samples were tested for the effect of total reaction volume 
on the binding efficiency of E2F1 species to DNA hot probe, a consideration based on 
the suspicion that excessively large reaction volume may decrease the binding 
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efficiency due to dilution. Similar to the EMSA result using neuronal lysates, our 
experimental results from HEK293 cells also shows a clear sign of a gel shift in the 
untransfected lysate lane (lane 2, Figure 3 and 4).  
The resulting EMSA data was inconclusive regarding the effect of DP1 on 
E2F1:DNA binding, while suggesting that a larger reaction volume may enhance the 
binding efficiency (Figure 4.5, bottom panel). DP1 positive lanes do not show 
enhanced band shift intensity in comparison to DP1 negative lanes. Reaction volume, 
however, may have an effect since the band intensity of 15 μl reactions appears 
stronger than that of 10 μl reactions. However, neither variable produced a dramatic 
increase in E2F1-DNA-bining signal. 
 Overall, our data so far suggests that E2F1 is able to bind both DNA and RNA, 
but it may have a stronger affinity for RNA. Also, certain amino acid sites, such as 
R125A and N152K, within the DNA binding domain of E2F1 could potentially 
display differential roles in DNA and RNA binding. However, these results are 
preliminary, and we are still in the process of optimizing the EMSA protocol. As a 
future direction of this project, we are preparing to test for the effect of ionic 
concentrations on E2F1:DP:DNA and E2F1:DP:RNA complex formation by changing 
the ionic make-up of our binding buffer used during EMSA (Jordan et al., 1994). We 
may also to perform EMSA reactions with affinity purified FLAG-E2F1 or GST-E2F1 
in order to increase the concentration of E2F1 bait and to eliminate concerns of 
endogenous protein in the cell lysates contributing to the observed probe shifts. 
Finally, switching from a biotin-based EMSA protocol to a more sensitive detection 
method such as radioactivity may be a necessary change to enhance baseline E2F1-
DNA binding signal.  
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Figure 4.2. Generation of E2F1 point mutants. Top panel, a schematic showing the 
minimal sequence of E2F1 containing functional DNA binding (amino acids 117-
191). in red along with the relevant amino acid sequence in which the mutated 
residues are located. Residues in red denote amino acids that contact DNA, asterisks 
refer to the residues that contact the DNA bases as opposed to the phosphodiester 
backbone. Western Blot showing successful overexpression of point mutant E2F1 
constructs in HEK293 cells. Wildtype FLAG-rE2F1 E2F1 (1-397) which lacks the 
final 40 C-terminal amino acids, serve as positive controls for overexpression.   
 
 
 
 
 
 
 
 
 
 119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. EMSA competition assay in neuronal lysates. Top panel. EMSA 
competition assay from rat primary neuronal lysates overexpressing C-terminal 
truncated wildtype rat E2F1 (1-397) with biotin-labeled DHFR DNA probe and either 
increasing concentrations of unlabeled DHFR DNA probe or unlabeled E1 C1 RNA 
probe used as cold competitor. The last lane represents a supershift attempt. Bottom 
panel. Densitometry analysis of the EMSA result from top panel. Relative signal 
intensities of the bands from DNA and RNA competiton assays were plotted against 
the amount (ng) of competition inhibitor added.  
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Figure 4.4. EMSA of select E2F1 point mutants. EMSA of E2F1 constructs 
containing point mutations R125A, L130A, N152K, and N170A overexpressed in 
HEK 293 cells. E1 RNA ligand was used as a cold competitor. 
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Figure 4.5. EMSA results with affinity-purified DP1. Top left panel. Flag-Dp1-
myc plasmid was used to transfect HEK293 cells with and without FLAG-E2F1 co-
transfection in HEK 293 cell line. Samples were run on gel in triplicate. Identical 
thirds of the transferred membrane were probed with FLAG, DP1, and Myc antibodies, 
respectively. All three antibodies detected DP1 over-expression. Interestingly, DP1 
expression level was markedly reduced by co-transfection with E2F1. Top right 
panel. Purification of Dp1 using FLAG affinity column. Dp1 eluate (lane 3) shows 
DP1 enrichment relative to unbound DP1 supernatant ‘flow-through’ following 
incubation with affinity column (Dp1 flow). Bottom Panel. EMSA testing for the 
effects of Dp1 and reaction volume on E2F1:DNA binding. 
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CHAPTER 5  -  DISCUSSION 
5.1  OVERVIEW  
One of the pressing needs facing the scientific and medical community is the 
development of effective therapies to manage neurodegenerative disease progression. In 
the case of HIV-associated neurocognitive disorders (HAND), the introduction of anti-
retroviral therapy (ART) to suppress viral replication has dramatically improved 
prognosis of HIV-positive patients by both preventing the immune-compromised final 
state of HIV disease known as AIDS and significantly reducing the incidence of HIV-
associated dementia, the most severe form of HAND (Childs et al., 1999, Sacktor et al., 
2001). However, the prevalence of more minor cognitive impairments has grown and 
current estimates suggest that 30-50% of HIV-infected patients suffer from some form of 
neurocognitive dysfunction (Sacktor et al., 2001, Heaton et al., 2010) (McArthur et al., 
2010). This shift in disease landscape is believed to be due to the increase in average 
lifespan of HIV-positive individuals on ART as well as potentially neurotoxic effects of 
ART drugs themselves (Sacktor et al., 2003, Sacktor et al., 2006, Sacktor et al., 2009). 
Recent evidence in both nonhuman primates with SIV-infection and in cultured primary 
cortical neurons has revealed significant neuronal damage resulting from ART (Akay et 
al., 2014).  In fact, studies have suggested that discontinuation of ART treatment may 
improve neurocognitive status of HIV-positive individuals suffering from HAND 
(Robertson et al., 2010). However, given the universal benefit that ART provides to 
patients by preserving immunity and lifespan, a major emphasis should be placed on 
developing adjunct therapies to use alongside ART in treating the neurological 
impairments in HAND.  
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 Toward that end, we have sought to define the neuronal pathways that promote 
neuronal damage and degeneration during HIV infection with the goal of identifying 
targets for therapeutic intervention. Two common death pathways that have been 
implicated in neuronal death are classical apoptotic signaling cascades involving the 
caspase family of cysteine proteases and necrotic pathways that utilize cysteine proteases 
called calpains. In advancing our understanding of HIV-induced neurodegeneration, one 
of our goals was to determine the relative contribution of caspases and calpains to cellular 
death processes in mature post-mitotic neurons. In Chapter 2, we assessed the effect of 
neuronal culture age on the capacity of neurons to induce calpain-mediated and caspase-
mediated death. We report that primary cortical neuronal cultures exhibited both caspase- 
and calpain-mediated neuronal death at 1 week of age. However at 3 weeks of age, a 
stage at which neurons have fully developed synaptic innervations and express a 
complete repertoire of NMDAR subunits, we observed that cultured cortical neurons 
maintain their ability to induce death through calpain pathways but no longer induce 
caspase-dependent death. This shift in death pathway capabilities is accompanied by an 
upregulation of calpain-1 and a downregulation of executioner procaspase-3 protein 
levels.  
In Chapter 3, we employed an in vitro model of HIV-induced neurotoxicity to 
identify a role for cell cycle protein E2F1 in calpain-mediated neuronal death. Our results 
revealed that cortical neuronal cultures from mice lacking functional E2F1 show reduced 
susceptibility to neuronal damage induced by conditioned media from HIV-infected 
monocyte-derived macrophage cultures (HIV-MDM). Furthermore, we identified 
neuronal E2F1 as a novel calpain substrate that is proteolytically cleaved to generate a 
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small, stable fragment following treatment with HIV-MDM supernatants.  This fragment 
is produced specifically in differentiated neurons and requires native conditions to 
prevent further calpain degradation, suggesting that calpain-mediated proteolysis of E2F1 
is cell-type specific and dependent on the native conformation of E2F1 and possibly other 
neuronal binding partners.  
Given the ability of E2F1 to bind RNA through its DNA binding domain, we 
hypothesized that the cytosolic localization of neuronal E2F1 may allow it to regulate 
local protein translation as an RNA-binding protein (Ishizaki et al., 1996, Darbinian et al., 
2006); unpublished data). In Chapter 4, we outline preliminary studies examining the 
RNA-binding capability of E2F1 by attempting to define the key residues within the 
DNA binding domain that govern the E2F1-RNA interaction.  
Taken together, these data: 1) identify calpain activation as a dominant pathway 
in causing death and damage of fully differentiated neurons, 2) implicate neuronal E2F1 
in a calpain-mediated death pathway during HIV infection of the CNS, and 3) highlight a 
need for understanding both the physiological role of full-length E2F1 in neurons and the 
function of the cleaved product during pathological conditions. 
 
5.2  CALPAINS AND CASPASES: CELL DEATH IN MATURE NEURONS  
Caspase-mediated signaling cascades are widely used by mammalian cells as a form of 
genetically programmed cellular suicide known as apoptosis. Originally identified in C. 
elegans, caspases were shown to enact a cell death mechanism that rapidly eliminates 
excess cells during development. The cells that activate this caspase death program are 
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predetermined based on cell lineage and activate cell death at predictable times (Lettre 
and Hengartner, 2006). Similarly, the proper development of the mammalian CNS 
requires activation of caspase-mediated apoptosis, providing a wave of cell death among 
proliferating neuroblasts and immature neurons that unsuccessfully compete for synaptic 
innervations and trophic factor support (Gagliardini et al., 1994, Yuan and Yankner, 
2000). Disrupting this process through genetic deletion of caspase-3 and caspase-9 in 
mice causes exencephaly, hyperplasia and perinatal lethality (Kuida et al., 1998, 
Pompeiano et al., 2000). Caspases have similarly been implicated in activating apoptosis 
in individual cells of various tissue types as a response to cellular stresses such as DNA 
damage, oxidative stress and hypoxia (Elmore, 2007). The rapid elimination of these 
damaged cells serves to protect the surrounding cells of the organism and in the case of 
DNA damage, to ensure that the defective cells do not proliferate and produce a 
genetically altered cell population.  
 However, the mature mammalian CNS primarily contains neurons that are 
postmitotic and that have established a complex network of synaptic connections with 
surrounding cells. Preserving these synaptic connections is critical for facilitating cell-
cell communication and maintaining intact neural circuitry. Given the dependence of the 
CNS on this synaptic network, a rapid elimination of a mature neuron would affect each 
of the surrounding cells with which it shares synaptic connections. Thus, the detrimental 
effects of rapid elimination of stressed or damaged neurons in the adult brain could 
outweigh any potential benefits, suggesting that caspase-directed apoptosis may be less 
likely when the CNS is fully developed. In fact, our results in cultured rat cortical 
neurons show a clear developmental effect on the induction of caspase-mediated neuronal 
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death. While H2O2 treatment was able to induce caspase-dependent neuronal death at an 
early culture age (1 week), caspase-mediated death was undetectable in cultures treated 
with H2O2 at 3 weeks of age, a time when synaptic surface receptor expression has 
matured (O'Donnell et al., 2006, Eugenin et al., 2011). Protein expression data from these 
cultures revealed a reduction in procaspase-3 protein levels in cultures at 3 weeks of age 
compared to those at 1 week, further supporting a decreased capacity to induce caspase-
mediated death as neuronal cultures mature.  This finding was mirrored by several studies 
both in vitro and in animal models demonstrating that procaspase-3 levels decrease 
during neuronal maturation and that caspase induction in response to stressors such as 
hypoxia and ischemia was dramatically attenuated with age (Hu et al., 2000, Yakovlev et 
al., 2001, Li et al., 2009).   
 Unlike caspase-mediated death that can take on the order of hours to minutes to 
commit a cell to death, calpain-mediated neuronal death can occur as part of a chronic, 
slow progressing disease state. Current evidence suggests that calpain dysregulation in 
the CNS becomes more likely with age in part due to increased expression of calpains 
and gradual depletion of its endogenous inhibitor calpastatin (Nixon et al., 1994, Mouatt-
Prigent et al., 1996, Rao et al., 2008).  Our results in cortical culture support those in vivo 
observations by showing that as caspase-3 expression and caspase-mediated neuronal 
death are downregulated in culture, calpain-1 expression increases and calpain-activated 
death becomes more prevalent. Using a similar cortical culture system to model age-
related neurodegeneration, Kim and colleagues observed this same increase in expression 
for both calpain-1 and calpain-2 isoforms as their cultures aged in conjunction with 
decreased procaspase-3 levels (Kim et al., 2007). However, numerous in vitro studies that 
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aim to model acute neuronal loss and chronic neurodegenerative states in the mature 
brain identify caspase involvement in neuronal death (Giovanni et al., 2000, Park et al., 
2000a, Kuwako et al., 2002, Benosman et al., 2007, Shiwany et al., 2009, Feng et al., 
2014). These studies often utilize neuronal cell lines or cultured primary neurons at an 
early age. Our findings underscore the importance of carefully considering culture age 
when interpreting data from in vitro studies. Indeed, our in vitro model of HIV-mediated 
neurotoxicity illustrates the critical role that culture age can play as HIVMDM treatments 
fail to elicit neuronal damage and loss at 7 days in vitro, but show significant neuronal 
loss at DIV 14 and DIV 21 (O'Donnell et al., 2006). Furthermore, our results and those of 
others suggest that calpain-mediated neuronal death predominates following neuronal 
maturation and that selecting older neuronal cultures for in vitro studies may be more 
physiologically relevant for modeling CNS diseases in the adult brain.  
 
5.3  A TRANSCRIPTION-INDEPENDENT FUNCTION FOR NEURONAL E2F1 
Traditionally, E2F1 research was aimed at understanding its function in proliferating 
cells. Studies of E2F1 have uncovered its role as a critical regulator of the G1-S phase 
transition during cell division as well as an inducer of cell death through its activation of 
transcriptional programs for DNA replication and classical apoptotic cascades, 
respectively (DeGregori and Johnson, 2006, Iaquinta and Lees, 2007). However, E2F1 
has also received considerable attention in the context of neuronal death and 
neurodegeneration. In vitro studies have implicated E2F1 transcriptional activation of 
apoptosis in cultured neurons and neuronal cell lines in response to a variety of cellular 
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stresses, including DNA damage, potassium deprivation, and Aβ toxicity (Park et al., 
1997, Giovanni et al., 2000, O'Hare et al., 2000, Park et al., 2000a, Park et al., 2000b). 
Furthermore, a number of cell cycle proteins including E2F1 and its transcriptional 
repressor Rb, show aberrant expression patterns in CNS neurons of patients with 
neurodegenerative diseases (Ranganathan et al., 2001, Herrup and Arendt, 2002, Jordan-
Sciutto et al., 2002a, Jordan-Sciutto et al., 2002b, Jordan-Sciutto et al., 2003, Akay et al., 
2011, Folch et al., 2012)(Akay, Lindl, 2011; Jordan-sciutto, Dorsey, 2003; Ranganathan, 
Scudiere, 2001; Herrup and Arendt, 2002; Jordan-Sciutto, Malaiyandi, 2002; Jordan-
Sciutto, Wang, 2002; Folch, Junyent, 2011). These unexpected observations along with 
discoveries of aneuploidy and DNA replication in postmitotic CNS neurons provided the 
hypothesis that the observed aberrant activation of cell cycle regulators represented an 
attempt at cell cycle re-entry that caused neuronal death and contributed to 
neurodegeneration (Mosch et al., 2007, Arendt, 2012).  
However, data from our lab suggests that E2F1 in neurons may have an alternate 
role to its traditional actions as a transcription factor in cell division and apoptosis.  We 
have observed a predominantly cytoplasmic localization of E2F1 in neurons both in vivo 
and in vitro (Jordan-Sciutto et al., 2002b, Wang et al., 2010, Ting et al., 2014). Despite 
reported E2F1 upregulation in neurons of patients with HIV encephalitis, studies from 
our in vitro model of HIV-induced neurotoxicity show no evidence of transcriptional 
activation of canonical E2F gene targets (Wang et al., 2010).  Furthermore, several 
studies have noted an ability of E2F1 to induce cell death through transcription-
independent mechanisms. For instance, we have shown that overexpression of 
transcriptionally-inactive E2F1 protein can induce calpain-mediated cell death in 
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HEK293 cells (Strachan et al., 2005). In cerebellar granular neuronal cultures, Hou et al. 
reported that overexpression of E2F1 lacking the transactivation domain induces 
apoptosis through modulation of NFκB protein levels (Hou et al., 2001). Our current 
studies confirmed the cytosolic localization of neuronal E2F1 and reveal a role for E2F1 
in HIV-induced neurotoxicity through a calpain-dependent pathway.  Additionally, we 
identified the stable accumulation of a calpain-cleaved E2F1 fragment in neurons and 
suggest that production of this cleavage product may serve as a neurotoxic event either 
through E2F1 physiological loss of function or through a toxic gain of function.  
 
5.4  IDENTIFYING THE SITES OF E2F1 CLEAVAGE 
Understanding the functional consequences of neuronal E2F1 cleavage will require the 
identification of the precise proteolytic sites within the E2F1 protein. This effort has been 
complicated by several biological and technical challenges. First, unlike proteases such as 
caspases and trypsins that have well-established cleavage site motifs, the rules governing 
substrate cleavage by calpains are poorly understood. Given the widespread involvement 
of calpain activity in neuronal physiology and neuronal damage, there have been 
numerous attempts to define a consensus sequence or preferred motif for calpain cleavage 
of its many substrates (Tompa et al., 2004, Cuerrier et al., 2005, DuVerle et al., 2011). 
Despite these efforts, no definitive method exists to predict cleavage sites and it is now 
generally appreciated that calpain cleavage site recognition involves secondary and 
tertiary structure considerations, making site predictions based on primary sequence 
difficult.  
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In the absence of reliable prediction tools, calpain cleavage sites are often 
identified by recapitulating substrate cleavage in vitro through incubation of recombinant 
substrate protein with activated calpain and then identifying cleavage sites through 
sequencing analyses. Interestingly, we found that incubation of recombinant E2F1 with 
activated calpain-1 in a cell-free system failed to produce the stabilized fragment 
observed in neurons. Additionally, calpain cleavage of E2F1 in overexpressing cell lines 
also failed to generate the stabilized fragment, suggesting that this calpain-cleaved 
isoform is uniquely produced in neurons. The current technical limitations of both 
commercially available and our custom-designed E2F1 antibodies have so far prevented 
immunoprecipitation of the E2F1 cleavage product from neuronal protein lysates. Our 
attempts to overexpress E2F1 in neurons in order to increase the potential input of 
cleaved E2F1 have similarly been unsuccessful, likely due to the presence of E2F 
consensus sites within the plasmid CMV promoter that allow E2F1 to shut off promoter-
driven expression when complexed with Rb or other binding proteins (Trouche et al., 
1997, Choi et al., 2005).  Thus, future attempts to isolate the calpain-cleaved E2F1 
product from neurons will focus on: 1) increasing input of E2F1 protein for future 
immunoprecipitations either by using an in vitro transcription/translation system or by 
identifying a plasmid promoter lacking E2F consensus sites that will support robust E2F1 
overexpression in neurons, and 2) performing a two-step chromatographic purification 
method consisting of either size-exclusion chromatography or ammonium sulfate 
precipitation followed by a DNA binding affinity column.  
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5.5  CALPAIN-CLEAVED E2F1:  A NEUROTOXIC ISOFORM 
We have been able to demonstrate through a calpain cleavage time course and via an 
epitope tagging approach that neuronal E2F1 is cleaved by calpain at least twice, once at 
the N-terminus and once at the C-terminus. Identifying the precise cleavage sites would 
be beneficial not only by clarifying the extent to which the terminal domains are 
disrupted within E2F1, but also by allowing overexpression studies of the cleavage 
product to conclusively assess its toxicity. Despite the current limitations that prevent this 
study, there are several pieces of evidence suggesting that calpain-cleaved E2F1 acts in a 
neurotoxic fashion. First, pharmacological inhibition of different NMDAR subunits 
revealed that E2F1 cleavage is dependent on stimulation of NR2B-containing receptor 
subtypes. NR2B-containing NMDARs are widely reported as extrasynaptic and viewed 
as the receptors mediating excitotoxicity (Zhou and Baudry, 2006, Liu et al., 2007). 
Moreover, the regions of the brain with higher NR2B expression such as the prefrontal 
cortex, hippocampus and basal ganglia are the same regions that are most susceptible to 
excitototoxicity and HIV-mediated neurodegeneration (Kim et al., 1998, Jordan-Sciutto 
et al., 2002b). Second, our model of HIVMDM-induced neurotoxicity promotes neuronal 
damage in a NR2B receptor-dependent and calpain-dependent manner, the same manner 
in which E2F1 is cleaved (O'Donnell et al., 2006, White et al., 2011). Finally, we have 
previously shown that overexpressing an N-terminal truncation of E2F1 in HEK293 cells 
causes calpain-dependent cell death, suggesting that E2F1 truncation can promote 
toxicity via a calpain pathway (Strachan et al., 2005). Taken together, these data support 
the view of calpain cleavage of E2F1 as a neurotoxic event (Figure 5.1).  
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Nonetheless, it is worth considering the possibility that E2F1 cleavage serves a 
neuroprotective function. In fact, calpain activation has been observed to have 
neuroprotective roles in certain toxicity models. For instance, calpain activation can 
attenuate neuronal death in hippocampal and mesencephalic slice cultures treated with 
the neurotoxin MPP+ through BDNF-dependent signaling (Jourdi et al., 2009). Given the 
disparity of Ca
2+
 required in vitro by calpain-1 and calpain-2, there has been a widely 
held belief that calpain-1 fulfills physiological roles while calpain-2 is activated under 
conditions of sustained calcium dysregulation. The recent development of isoform-
specific pharmacological inhibitors of calpains has helped test this theory. While recent 
findings present conflicting results, at least one study has reported results that support a 
neuroprotective role for calpain-1 and a neurotoxic role for calpain-2 (Lee et al., 2013, 
Wang et al., 2013). Using these isoform-specific calpain inhibitors along with isoform-
specific knockdown approaches could help identify which calpain isoform is responsible 
for processing E2F1 in our HIVMDM-treated cultures and shed light on the role of 
calpain-cleaved E2F1 in neuronal viability.  
 
5.6  E2F1 IN SYNAPTIC PHYSIOLOGY 
The functional implications of a potential E2F1 loss-of-function are difficult to appreciate 
without understanding the role of E2F1 in neuronal physiology. Our current 
understanding of neuronal E2F1 function is hampered by the absence of a true E2F1 
knockout mouse model. Future development of a conditional ‘Cre-LoxP’ E2F1 knockout 
animal model will help address E2F1 physiological functions through studies of the 
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effects of neuron-specific and brain region-specific E2F1 deletion. In spite of this 
limitation, current evidence supports several possible roles for neuronal E2F1.  
In cultured hippocampal neurons, E2F1 expression is punctate and co-localizes 
with the post-synaptic marker PSD-95(Ting et al., 2014).  Biochemical fractionation 
similarly reveals enrichment of E2F1 in synaptic fractions (Ting et al., 2014). 
Furthermore, mice lacking functional E2F1 exhibit age-dependent depletion of critical 
synaptic proteins such as PSD-95, NMDAR subunits NR1 and NR2A, and Synaptic Ras 
GTPase activating protein (SynGAP)  as well as memory and olfactory deficits with 
mirroring age-dependent onset (Ting et al., 2014).  These findings suggest that E2F1 may 
contribute to maintenance of synaptic structure or physiology in the adult brain.  
Interestingly, the E2F1 amino acid sequence contains multiple P-X-X-P motifs 
known to bind SH3 domains (Alexandropoulos et al., 1995).  A number of synaptic 
proteins contain SH3 domains, including the scaffolding proteins PSD-95 and SAP97, as 
well as amphiphysin I (Vandanapu et al., 2009, Neuvonen et al., 2011). These proteins 
are involved in a variety of synaptic processes including ion channel/receptor clustering, 
membrane trafficking, and synaptic vesicle recycling. Identifying potential binding 
interactions between E2F1 and the SH3 domains of these proteins or with other synaptic 
proteins will be instrumental in clarifying the significance of E2F1 synaptic localization. 
Additionally, these interactions may be disrupted during HAND following calpain 
cleavage of E2F1, contributing to synaptic dysfunction and HIV-associated neurotoxicity. 
Interestingly, we found that protein conformation was critical for production of the 
stabilized calpain-cleaved E2F1 isoform, suggesting that unique binding partners in 
neurons may underlie the cell type-dependent nature of its production by protecting 
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regions of the E2F1 protein from further degradation. Thus, identifying the synaptic 
binding interactions with E2F1 that remain preserved in our in vitro model of HAND 
may have important implications for understanding the novel calpain processing of E2F1 
in neurons. 
  Given the important role of calpain in synaptic plasticity and specifically in the 
induction of long-term potentiation (LTP), it is possible that the calpain-cleaved E2F1 
isoform may also participate in this process (Wu and Lynch, 2006). In fact, recent 
findings regarding CDK5 regulation in neurons show that its activator p35 is cleaved by 
calpain to p25 not only during pathological conditions, but also following physiological 
neuronal activity. Transient, NR2B-dependent production of p25 by calpain was shown 
to enhance LTD in hippocampal slice culture and aid in memory extinction in mice 
expressing a noncleavable p35 protein (Seo et al., 2014).  Development of a calpain-
resistant E2F1 knock-in mouse model would similarly allow us to assess whether 
inhibiting E2F1 cleavage influences synaptic remodeling and ultimately, the potential 
implications for learning and memory. 
 
5.7  E2F1 AND CALCIUM REGULATION 
It is well-established that intracellular Ca
2+ 
levels govern calpain activation. Interestingly, 
a number of calpain substrates are involved in regulating calcium homeostasis. Under 
conditions of elevated intracellular Ca
2+ 
concentrations, cleavage of these substrates often 
exacerbates calcium dysregulation and creates a positive-feedback pathway to amplify 
calpain activity.  For instance, the Type 1 IP3 receptor, which functions as an ER calcium 
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channel, disrupts intracellular Ca
2+
 buffering when cleaved by calpain (Kopil et al., 
2012). L-type Ca
2+
 channels in cultured neurons are cleaved by calpain, leading to C-
terminal truncation of their α1 subunit and enhanced Ca
2+
 influx (Klockner et al., 1995, 
Hell et al., 1996). Similarly, the plasma membrane Na
+
/Ca
2+
 exchanger (NCX) has been 
shown to be cleaved by calpain during excitotoxic stress, inhibiting its Ca
2+ 
extrusion 
capabilities (Bano et al., 2005).  Interestingly, neuronal E2F1 has been reported to bind 
Necdin, a factor involved in maintaining the terminally differentiated identity of 
postmitotic neurons (Kuwako et al., 2004). Further, Necdin has been linked to 
intracellular calcium regulation through its interaction with NEFA, a calcium-binding 
protein located on the ER cisternae which regulates ER calcium release (Taniguchi et al., 
2000). We have previously found that transcriptionally-inactive N-terminally truncated 
E2F1causes cell death when overexpressed in HEK293 cells (Strachan et al., 2005). This 
truncated E2F1 product localizes to the cytoplasm much like calpain-cleaved E2F1 and 
induces death through a calpain-dependent mechanism. Together, these findings suggest 
that E2F1 may play a role in calcium homeostasis and that calpain-cleaved E2F1 could 
promote calpain amplification by enhancing intracellular calcium elevation. Future work 
will determine whether an E2F1-Necdin binding interaction might be involved in calcium 
regulation and whether calpain cleavage of E2F1 during HIV-mediated neurotoxicity 
disrupts this interaction and this putative function. In addition to this candidate approach, 
a system-wide effort to identify neuronal binding proteins should be carried out to 
identify the neuronal interactome of E2F1. This unbiased strategy could confirm an 
E2F1-Necdin interaction while identifying binding factors involved in other potential 
processes. 
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5.8  NEURONAL E2F1: A PUTATIVE RNA-BINDING PROTEIN 
We and others have observed that E2F1 can bind synthetic RNA ligands in vitro (Ishizaki 
et al., 1996, Darbinian et al., 2006). We have also observed that E2F1 interacts with 
cellular RNA from rat cortex and that this interaction is dependent on the ‘winged helix’ 
DNA binding domain (unpublished observation). Considering that localization of 
neuronal E2F1 is predominantly cytoplasmic, E2F1 participation in RNA binding and 
local translational regulation provides an appealing mechanism for its function in neurons 
and a target of disruption during HIV-induced neuronal damage. Interestingly, several 
DNA-binding proteins in the ‘winged helix’ superfamily carry out RNA-binding 
functions including the Lupus La protein and SelB, both of which function as translation 
factors in the cytosol (Intine et al., 2003, Yoshizawa et al., 2005).  In our current studies, 
we attempted to determine the identity of the RNA binding domain of E2F1 through a 
combined approach utilizing site-directed mutagenesis and EMSA. As we continue these 
studies and identify E2F1 point mutants with disrupted RNA binding ability, we aim to 
use these point mutants in overexpression studies to assess their influence on neuronal 
viability.  
Further work to investigate E2F1 RNA-binding in neurons will be greatly aided 
by identification of the RNA species that E2F1 binds. So far, BLAST searches have been 
difficult to carry out given the short sequence and secondary structure of the synthetic E1 
RNA ligand with which E2F1 interacts. A more promising unbiased approach will rely 
on RNA immunoprecipitation methodologies in conjunction with real-time PCR 
techniques to isolate E2F1-associated RNA and identify the individual transcripts. Once 
they are identified, studies to explore their translational regulation during basal and 
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neurotoxic conditions could show whether E2F1-RNA binding and translational 
repression is disrupted during HIV-associated neurodegeneration while pinpointing the 
individual transcripts that are affected.  
Putative RNA-binding functions of E2F1 could help regulate local translation in 
several neuronal contexts. One such context is synaptic plasticity, which depend on local 
protein synthesis to facilitate rapid changes in synaptic membrane organization and 
surface receptor distribution (Martin and Zukin, 2006, Derkach et al., 2007). Protein 
synthesis inhibitors have been shown to block induction of LTP and a host of RNAs have 
been identified in dendrites along with protein synthesis machinery (Bradshaw et al., 
2003, Martin and Zukin, 2006, Pfeiffer and Huber, 2006). Local protein synthesis also 
plays an important role in axon guidance, where the growth cone must continually 
respond to chemotactic signals in the surrounding environment (Yoon et al., 2009).  For 
instance, local translation of β-actin is required during Ca2+-mediated growth cone 
turning (Yao et al., 2006). Intriguingly, calpain activation has also been documented both 
in synaptic potentiation and in axon pathfinding, suggesting a possible regulatory link 
between calpain processing of E2F1 and E2F1-RNA binding, wherein E2F1 cleavage 
triggers release of bound, translationally repressed transcripts (Qin et al., 2010, Baudry et 
al., 2013). Given our results that calpain-cleaved E2F1 is capable of being produced at all 
culture ages, it is quite possible that calpain-cleaved E2F1is transiently generated during 
neurite outgrowth. Thus, performing parallel RNA immunoprecipitation reactions with 
full length and calpain-cleaved E2F1 could identify which E2F1-bound transcripts are 
released following calpain cleavage of E2F1either in physiological or pathophysiological 
settings. 
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Although we do not observe detectable levels of E2F1 in nuclear fractions of 
cultured cortical neurons and fail to detect expression of canonical E2F gene targets in 
our model of HIV-induced neurotoxicity, it is still possible that neuronal E2F1 retains 
some role as a transcription factor. In fact, we have previously observed that E2F1 
shuttles between the neuronal cytosol and nucleus, and that inhibiting the nuclear export 
receptor Crm1 causes nuclear accumulation of E2F1. Furthermore, calpain cleavage of 
certain substrates has been shown to induce nuclear translocation and influence 
transcriptional programs. For example, in cultured hippocampal neurons treated with 
glutamate or NMDA, calpain has been reported to cleave the transcription factor beta-
catenin at its N-terminus, producing stable truncation products that subsequently 
translocate to the nucleus and activate gene transcription (Abe and Takeichi, 2007).  
Following calpain processing of p35 to p25, Cdk5 translocates to the nucleus where it has 
been shown to inhibit MEF2D, a transcription factor that regulates neuroprotective genes 
(O'Hare et al., 2005, Smith et al., 2006). To aid in the investigation of E2F1 RNA-
binding function, we are in the process of screening for nucleotide analogs that bind 
E2F1 and selectively disrupt E2F1: RNA binding while leaving E2F1: DNA complexes 
unaffected. This tool will help identify RNA binding effects of E2F1 that are unrelated to 
E2F1 transcription factor activity. 
 
5.9 CLINICAL UTILITY OF CALPAIN-CLEAVED E2F1 
Calpain activation has been implicated in a host of neurodegenerative conditions (Camins 
et al., 2006). Despite a well-documented role in neuronal damage, calpains are 
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ubiquitously expressed and are critical for a variety of physiological processes in 
different cell types. With the physiological functions of calpains in mind, it is currently 
difficult to formulate a therapeutic strategy involving calpain inhibition. If a strategy is to 
be devised to selectively address detrimental calpain activities in a particular disease, it 
will be critical to understand the role of each calpain substrate, the functional implication 
of its cleavage, and the disease in which it is processed. By identifying a subset of these 
substrates whose cleavage significantly contributes to disease pathology, it may be 
possible to therapeutically target calpain in a substrate-specific manner that eliminates 
unwanted proteolytic events while sparing those that are beneficial.  
Recent work has employed just such an approach with the calpain substrate 
mGluR1α that is cleaved during excitotoxicity, leading to enhanced calcium 
dysregulation (Wei et al., 2008). To block this cleavage event, a decoy peptide was 
designed containing the mGluR1α sequence spanning its calpain cleavage site fused to a 
cell permeable sequence from the HIV TAT protein. This decoy peptide successfully 
prevented mGluR1α cleavage by calpain and provided neuroprotection when 
administered to NMDA-treated cortical cultures and when injected systemically into mice 
with ischemic injury (Wei et al., 2008). Given this promising result, it may be worthwhile 
to pursue substrate-specific strategies for attenuating certain calpain cleavage events.  
 We have identified E2F1 as a novel calpain substrate and provided evidence 
suggesting that calpain-cleaved E2F1 contributes to HIV-mediated neuronal damage. 
While there is a clear need for adjunctive therapies to treat patients with HAND, the 
potential of calpain-cleaved E2F1 as a therapeutic target will depend in part on the nature 
of neuronal E2F1 physiologic function and the functional consequences of its proteolytic 
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processing. Furthermore, a specific strategy targeting E2F1 cleavage like the one above 
for mGluR1α will necessitate identification of the precise cleavage sites within the E2F1 
sequence. Thus, future studies are warranted to explore neuronal E2F1 function and to 
define the sequence of calpain-cleaved E2F1 and its role in neurons.  
 Aside from the potential therapeutic value of calpain-cleaved E2F1, calpain-
cleaved E2F1 may hold promise as a diagnostic marker. Our studies identified production 
of calpain-cleaved E2F1 in human fetal neurons and observed a low molecular weight 
E2F1 isoform in a subset of midfrontal cortex autopsy samples from patients with 
HAND.  A larger tissue sample size will need to be evaluated to determine whether there 
is a significant correlation between lower molecular weight E2F1 presence and disease 
status. If a correlation does exist, generating site-directed antibodies specific for calpain-
cleaved E2F1 may have utility in helping diagnose HAND. A recent study found that 
measuring levels of activated calpain in the CSF of AD patients improved diagnostic 
accuracy as part of a multivariate analysis (Laske et al., 2014). Additionally, the 
diagnostic value of calpain-cleaved αII-spectrin in serum was recently demonstrated in 
predicting recovery of athletes following concussions, suggesting that calpain substrates 
may serve as diagnostic marker for mild traumatic brain injury in blood samples (Siman 
et al., 2013, Siman et al., 2014). Experiments to detect calpain-cleaved E2F1 levels in 
CSF and serum will help determine whether there is similar utility for this E2F1 isoform 
in diseases such as HAND and potentially other CNS conditions. Ultimately, detecting 
calpain-cleaved E2F1 as part of a diagnostic signature may maximize diagnostic accuracy 
and disease specificity. Future work is needed to demonstrate whether calpain-cleaved 
E2F1 or other calpain substrates are suitable for this type of application. 
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Figure 5.1. Proposed mechanism for neuronal E2F1 in HIV-induced neurotoxicity. 
HIV-infected monocytes cross the blood-brain barrier and differentiate into macrophages 
in the brain parenchyma. There, they release excitotoxins and inflammatory factors such 
as glutamate into the extracellular environment (1).  These factors bind and activate 
NMDA receptors on CNS neurons (2), causing calcium influx (3) and subsequent 
activation of the cysteine protease calpain (4). Activated calpain cleaves multiple 
substrates including E2F1, producing a stabilized protein fragment with truncations at the 
N- and C-terminus (5). Calpain-cleaved E2F1 may contribute to calpain-mediated 
neuronal damage observed in NMDA receptor-mediated neurotoxicity (6). 
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